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19Zusammenfassung
Zusammenfassung
Die Polyomavirus-assoziierte Nephropathie (PVAN) ist eine bedeutsame Ursache des 
Organsversagens nach Nierentransplantation und betrifft bis zu 10% der Patienten nach 
Nierentransplantation. Die meisten Fälle werden durch das BK Virus (BKV) im Rahmen 
der immunsuppresiven Therapie ausgelöst.
Das angeborene Immunsystem spielt eine wichtige Rolle bei der Erkennung viraler 
Infektionen und der Initiierung antiviraler Immunantworten. Nukleotidsequenzen viraler 
RNA werden pathogen- und zelltypspezifisch durch eine Vielzahl von molekularen 
Mustererkennungsrezeptoren, den Pattern-Recognition Receptors (PRPs) detektiert. 
Die Erkennung viraler RNA führt zu einer Aktivierung einer Signaltransduktionskaskade 
mit Aktivierung von NF-κB und der Synthese von antiviralen Mediatoren wie Typ I 
Interferonen und inflammatorischen Zytokinen.
Um die antiviralen Antworten des renalen tubulären Epithels zu untersuchen, analysierten 
wir die mögliche Beteiligung der viralen dsRNA Rezeptoren Toll-like Rezeptor 3 
(TLR3) und retinoic acid inducible gene-I (RIG-I) in Transplantnierenbiopsien von 
Patienten mit einer PVAN, in humanen Sammelrohrepithelien (HCDCs) in Kultur nach 
Stimulation mit polyriboinosinic: polyribocytidylic acid (poly(I:C)), einem synthetischen 
Analogon viraler RNA sowie in einem Polyomavirus BK (BKV) Infektionsmodell. 
Die Immunfluoreszenzdoppelfärbung für BKV und TLR3 zeigte ein starkes Signal in 
Epithelien der distalen kortikalen Tubuli und Sammelrohre. In mikrodisseziierten 
tubulointerstitiellen Kompartimenten von Patienten mit PVAN war die mRNA Expression 
von TLR3 erhöht, aber nicht die Expression von RIG-I. Zusätzlich zeigten HCDCs eine 
intrazelluläre Expression von TLR3; eine Aktivierung von TLR3 und RIG-I durch poly(I:C) 
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führte zu einer erhöhten mRNA Expression von Zytokinen, Chemokinen und IFN-β. 
Diese Immunantwort konnte spezifisch durch siRNA für TLR3 geblockt werden.
Zusammenfassend führt eine Infektion von HCDCs mit BKV zu einer gesteigerten 
Expression von Zytokinen und Chemokinen, was schließlich zu einer effizienten 
antiviralen Immunantwort mit Hochregulation von TLR3 und RIG-I ohne Aktivierung von 
IL-1β oder von Komponenten des Inflammasom-Weges führt.
Die PVAN führt somit zu einer antiviralen Immunantwort mit Aktivierung des angeborenen 
Immunsystems und einer vermehrten Expression von inflammatorischen Zytokinen, 
Chemokinen und Typ I Interferonen.
21Summary
Summary
Polyomavirus-associated nephropathy (PVAN) is an emerging cause of significant 
kidney transplant dysfunction affecting up to 10% of patients, often leading to graft 
loss. Most cases of PVAN are elicited by BK virus (BKV) in the context of intense 
immunosuppression. 
The innate immune system plays a critical role in recognizing viral infections and evoking 
initial antiviral responses. Nucleotides from viral RNA are recognized in a pathogen- 
type- and cell-type-specific manner by a variety of pattern recognition receptors (PRRs). 
Recognition of viral RNA triggers downstream signaling cascades leading to activation 
of NF-κB and induces antiviral mediators such as type I interferons (IFNs) and proin-
flammatory cytokines. 
In order to identify antiviral responses of the renal tubular epithelium, we analysed the 
potential activation of the viral dsRNA recognition receptors Toll-like receptor 3 (TLR3) 
and retinoic acid inducible gene-I (RIG-I) in allograft biopsy samples of patients with 
PVAN, in cultured human collecting duct cells (HCDCs) after stimulation by the dsRNA 
mimic polyriboinosinic:polyribocytidylic acid (poly(I:C)) and in a model of polyomavirus 
BK (BKV) infection. Immunofluorescence doublestaining for BKV and TLR3 revealed 
strong signals in epithelial cells of distal cortical tubules and the collecting duct. In 
microdissected tubulointerstitial specimen, TLR3, but not RIG-I mRNA expression, was 
increased in PVAN. In addition, HCDCs expressed TLR3 intracellularly and activation 
of TLR3 and RIG-I by poly(I:C) enhanced the mRNA expression of cytokines, chemok-
ines and IFN-β. This inflammatory response could be specifically blocked by siRNA to 
TLR3. Finally, the infection of HCDCs with BKV enhanced the expression of cytokines 
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and chemokines, leading to an efficient antiviral immune response with TLR3 and RIG-I 
upregulation without activation of IL-1β or components of the inflammasome pathway.
Thus, we concluded that in PVAN, activation of innate immune defense mechanisms 
is involved in the antiviral and anti-inflammatory response leading to the expression of 
proinflammatory cytokines, chemokines and type I IFNs. 
CHAPTER 1
INTRODUCTION
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1. Introduction
1.1. Innate immune system
The immune system in mammals can be divided in two branches: innate immunity 
which is phylogenetically conserved and is present in almost all multicellular organisms 
(1) and adaptive immunity which detects non-self through recognition of peptide anti-
gens using antigen receptors expressed on the surface of B and T cells and also affords 
protection against re-exposure to the same pathogen (2). The response initially taking 
place is the innate immune response, which is responsible for initiating inflammatory 
and immune processes to resolve infections and repair injured tissues. 
The innate immune system is an evolutionally conserved mechanism that plays a critical 
role in recognizing and eliminating invading pathogenic microorganisms by discriminat-
ing between self and non-self. It can be divided in three classes: (i) local recognition 
of infection and injury, which potentiates inflammatory responses and the initiation of 
innate immunity; (ii) systemic activation of innate immunity by infection or injury and 
release of inflammatory mediators; (iii) homeostatic interactions between innate immune 
system and environmental stimuli (3). 
Due to their molecular heterogeneity and rapid evolution, the reliable detection of patho-
gens is a hard task. 
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1.1.1. Cells of the innate immune system
The cells involved in the innate immune system include natural killers (NKs), dendritic 
cells (DCs), macrophages, γ/δT lymphocytes, neutrophils, basophils, eosinophils, and 
B-1 cells (4, 5). These cells express a set of germline encoded pattern recognition 
receptors (PRRs) that are able to recognize conserved molecular patterns associated 
with microbial pathogens (6). These receptors sense the pathogen and induce a rapid 
inflammatory response by the production of proinflammatory cytokines and  chemokines, 
stimulating the killing of infected or transformed cells, or stimulating phagocytosis or 
apoptosis. They can also upregulate expression of co-stimulatory mole cules, subse-
quently initiating the adaptive immunity.
DCs and macrophages, in addition to their role in innate immunity, also act as a link to 
the adaptive immune system. The activation of these cells is triggered by the PRR sig-
nals that convert them in potent antigen-presenting cells (APCs) capable of promoting 
the expansion and effector differentiation of T cells by the presentation of antigens (5, 7).
However, specialized immune cells are often not the first cells to encounter patho-
gens. The epithelium, being at the interface between the internal and external environ-
ment, constitutes the primary cellular barrier. Epithelial cells (ECs) possess pathogen- 
recognition mechanisms that enable them to respond to microorganisms by the 
expression of PRRs, thereby initiating the first steps in the host-pathogen interaction 
(8,  9). By the expression of these receptors, ECs are able to induce the production 
of antimicrobial and proinflammatory molecules, playing a role in the first responses 
against the pathogens as well as in the initiation of adaptive immune responses.
This communication between innate and adaptive immune systems, which involves cell-
cell interactions, enables the effective recognition and elimination of invading pathogens, 
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with minimal damage to the host, and provides protection from re-infection with the same 
pathogen.
1.1.2.  Pattern recognition receptors (PRRs) and pathogen-
associated molecular patterns (PAMPs)
The innate immune system senses microbial infection and recognizes micro organisms 
via a variety of germline-encoded recognition receptors. PRRs recognize conserved 
 features from a broad spectrum of microbial components, known as PAMPs, and ini-
tiate specific downstream signaling pathways leading to the activation of NF-κB and 
production of cytokines, including inflammatory cytokines, chemokines and type I inter-
ferons (IFNs) (6, 10, 11).
PAMPs are appropriated for innate immune recognition for three main reasons: i) they 
are invariant among microorganisms of a given class; ii) they are products of pathways 
that are unique to microorganisms, allowing discrimination between self and non-self 
molecules; iii) they have essential roles in microbial physiology limiting the ability of 
the microorganisms to evade innate immune recognition through adaptive evolution 
of these molecules (5, 12). PAMPs can include bacterial components, fungus compo-
nents, parasite components and virus components (Table 1).
The Toll-like receptor (TLR) family is the best characterized class of PRRs that partic-
ipates in the recognition of microbial components, but more recently it has become 
apparent that another series of PRRs, retinoic acid-inducible gene-I (RIG-I)-like recep-
tors (RLRs) and nucleotide binding oligomerization domain (NOD)-like receptors (NLRs), 
also play an important role in the innate immune response (6) (Table 1).
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Table 1. The roles of TLRs, RLRs and NLRs in pathogen recognition.
PRRs  
(structure) 
Adapters  
(structure)
PAMPs/ 
Activators
Species
TLR
TLR1–TLR2 (LRR–TIR) MyD88 (TIR–DD),  
TIRAP (TIR)
Triacyl lipopeptides Bacteria
TLR2–TLR6 (LRR–TIR) MyD88, TIRAP Diacyl lipopeptides
LTA
Zymosan
Mycoplasma
Bacteria
Fungus
TLR2 (LRR–TIR) MyD88, TIRAP PGN
Lipoarabinomannan
Porins
tGPI-mucin
HA protein
Bacteria
Mycobacteria
Bacteria (Neisseria) 
Parasites 
(Trypanosoma) 
Virus (Measles virus)
TLR3 (LRR–TIR) TRIF (TIR) dsRNA Virus
TLR4 (LRR–TIR) MyD88, TIRAP, TRIF, 
TRAM (TIR)
LPS
Envelope proteins
Bacteria
Virus (RSV, MMTV)
TLR5 (LRR–TIR) MyD88 Flagellin Bacteria
TLR7 (LRR–TIR) MyD88 ssRNA RNA virus
hTLR8 (LRR–TIR) MyD88 ssRNA RNA virus
TLR9 (LRR–TIR) MyD88 CpG DNA
DNA
Malaria hemozoin
Bacteria
DNA virus
Parasites
mTLR11 (LRR–TIR) MyD88 Not determined
Profilin-like molecule
Bacteria (uropatho-
genic bacteria)
Parasites (Toxoplasma 
gondii)
RLR
RIG-I 
(CARDx2–helicase)
IPS-1 (CARD) RNA (5´-PPP ssRNA, 
short dsRNA)
Virus
MDA5 
(CARDx2–helicase)
IPS-1 RNA (poly IC, long 
dsRNA)
Virus
LGP2 (helicase) RNA Virus
NLR
NOD1/NLRC1 
(CARD–NBD–LRR)
RICK (CARD), CARD9 
(CARD)
iE-DAP Bacteria
NOD2/NLRC2 
(CARDx2–NBD–LRR)
RICK, CARD9 MDP Bacteria
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NALP3/NLRP3 
(PYD–NBD–LRR)
ASC (PYD–CARD) 
CARDINAL 
(PYD–FIND)
MDP
RNA
ATP
Toxins
Uric acid, CPPD, 
amyloid-β
Bacteria
Bacteria, Virus
Bacteria? Host?
Bacteria
Host 
NALP1/NLRP1 
(CARD–FIND–NBD–
LRR-PYD)
ASC Anthrax lethal toxin Bacteria 
IPAF/NLRC4 
(CARD–NBD–LRR)
Flagellin Bacteria 
NAIP5 
(BIRx3–NBD–LRR)
Flagellin Bacteria 
Adapted from: Int. Immunol. 21, 317–337 (2009).
1.1.3.  Innate immune recognition of viral infection / 
Recognition of viral infection by PRRs
The innate immune system detects viral infections and senses the virus via their nucleic 
acid genome or as a result of their replicative or transcriptional activity, and evokes ini-
tial antiviral responses (13). These responses depend on different sensor systems that 
detect PAMPs and initiate specific downstream signaling pathways leading to activation 
of NF-κB and IRF and induce antiviral mediators such as type I IFNs that play a central 
role in the elimination of the viruses, and proinflammatory cytokines such as IL-6, TNF-α 
and IL-12 (14, 15). PAMPs are detected by PRRs that signal the presence of infection 
sensing critical viral components such as double-stranded (ds)RNA, single-stranded 
(ss)RNA, and ds or ssDNA
PRRs implicated in nucleic acid recognition can be divided in two groups based on cel-
lular localization: PRRs localized in the endosome and PRRs localized in the cytoplasm 
of the cell.
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Three classes of PRRs have been shown to sense viral components in innate immune 
cells, playing an essential role in the production of type I IFNs and proinflammatory 
cytokines: TLRs, RLRs and NLRs (13).
TLR3, TLR7, TLR8 and TLR9, which are localized to endosomes, represent a TLR sub-
family that recognizes nucleic acids (16). TLR3 recognizes dsRNA, which is produced 
by many viruses during replication. TLR7 recognizes ribonucleic acid homologues such 
as imiquimod, resiquimod (R848) and loxoribine, and ssRNA while TLR9 recognizes 
unmethylated 2´-deoxyribo (cytidine-phosphate-guanosine)(CpG) DNA motifs present 
in bacterial and viral DNA (17, 18, 19). TLR8 is phylogenetically close to TLR7 mediating 
recognition of ssRNA and R-848 (20).
RLRs comprise a family of cytoplasmic proteins that function as alternative PRRs 
through recognition of dsRNA produced during viral replication (21).
NLRs constitute a large family of intracellular PRRs, such as NLRP-3, which detects the 
presence of dsRNA and induces the catalytic activity of caspase-1, which is essential 
for cleavage of pro-interleukin-1β (IL-1β) to the mature form (22, 23).
Besides these three families of receptors, more recently it has also been described a 
member of the PYHIN (pyrin and HIN domain-containing protein) family, named absent 
in melanoma 2 (AIM2), which senses foreign cytoplasmic dsDNA (24).
This work focuses on two main dsRNA receptors, TLR3 and RIG-I, with a short over-
view about NLRP3 and AIM2 receptors.
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1.1.3.1. Toll-like Receptors
So far, 13 murine TLRs and 10 human TLRs have been identified (25). TLRs comprise a 
subfamily within the larger superfamily of interleukin (IL) receptors showing a similarity 
within their cytoplasmic regions and termed a Toll/IL-1 receptor (TIR) domain. The TIR 
domain is characterized by the presence of three highly homologous regions known as 
boxes 1, 2 and 3. In contrast, the extracellular portions of both types of receptors are 
quite distinct. The IL-1 receptors possess three immunoglobulin-like domains, whereas 
TLRs bear leucine-rich repeats (LRRs) in the extracellular domain (26, 27) (Figure 1).
The TIR domain, located in the cytosol in all TLRs, associates with TIR-domain containing 
adaptors molecules, such as MyD88 (myeloid differentiation primary response gene 88), 
TRIF (TIR-domain-containing adaptor-inducing interferon-β), TIRAP (TIR-containing 
IL-1R TLR
lg-like
domain
LRRs
TIR domain
Box 1
Box 2
Box 3
Figure 1. TLR structure. 
Taken from: Nat. Rev. Immunol. 4, 499–511 (2004).
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adaptor protein), and TRAM (TRIF-related adaptor molecule) (28, 29, 30). Except for 
TLR3, MyD88 is involved in all TLR-mediated signaling (31, 32) whereas TRIF is involved 
in TLR3 and MyD88-independent TLR4 signaling (28). TIRAP is involved in the Myd88- 
dependent signaling pathway through TLR2 and TLR4 (29), and TRAM is specifically 
involved in the Toll-like receptor-4 mediated MyD88-independent signaling pathway (30).
Unlike the other TLRs, which are expressed mainly on cell surface, TLR3, 7, 8 and 9, 
involved in the recognition of nucleic acids, are localized within endolysosomal com-
partments (Figure 2).
This work mainly focuses on the dsRNA recognition receptors. Therefore, TLRs that 
recognize non-nucleic acid molecules will not be described here.
Bacterial ﬂagellin
Toxoplasma proﬁlin (PFTG)
Bacterial
lipopeptides LPS
TLR5/11/12 TLR1/2/6 TLR4
MyD88 IRAK1
IRAK4 IRAK4
IRAK1
IRAK1
IRAK1
IRAK4
IRAK1
MyD88
MyD88
TIRAP
TRAM
TRIF
RIP1
TAK1
TRAF6
TRAF3
TRAF6
TRAF3
TRAF6
NEMO NEMOIKKγ
IKKα IKKβ
IKKγ
IKKα IKKβ
IKKεIκB
p50 p65
P
P
P P
PIκB
p50 p65
p50 p65
p50 p65
p50 p65
p50 p65
TBK1
TBK1
IRF3 IRF3 IRF7 IRF7
IRF3 IRF3 IRF7 IRF7
MAP kinase
Endosome
ssRNA/imiquimod
dsRNA dsDNA
TLR3
TLR7 TLR8 TLR9
Proinﬂammatory cytokines
IL-6, IL-8, IL12, TNFα
Proinﬂammatory cytokines
IL-6, IL-8, IL12, TNFαIFNβ, IFN-inducible genes IFNα, IFN-inducible genes
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1.1.3.1.1. TLR signaling pathways
1.1.3.1.1. a) MyD88-dependent pathway
Stimulation of TLRs by microbial components triggers expression of several genes that 
are involved in immune responses. Many TLRs induce inflammatory responses activat-
ing a common signaling pathway mediated by the adaptor molecule MyD88 which binds 
to the cytoplasmic domain of the TLRs through their respective TIR domains. When 
associated with a TLR, MyD88 recruits members of the IL-1 receptor-associated kinase 
(IRAK) family such as IRAK4, IRAK2 and IRAK1, through a DD-DD interaction (33, 34). 
Activated IRAKs form a complex with tumor necrosis factor (TNF) receptor- associated 
factor 6 (TRAF6) interacting with Ubc13 and Uev1A (35), leading to the activation of two 
distinct pathways: (i) activation of AP-1 transcription factors through activation of MAP 
kinases; (ii) activation of TAK1/TAB complex, which activates the IκB (IKK) complex 
consisting of IKKα, IKKβ and NEMO/IKKγ. IKK complex phosphorylates IκB resulting 
in nuclear translocation of NF-κB and activation of NF-κB-dependent genes, such as 
TNF-α, IL-1 and IL-6 (27, 36) (Figure 2). This pathway is used by all TLRs except TLR3.
1.1.3.1.1. b) MyD88-independent/TRIF-dependent pathway
The Myd88-independent pathway exists downstream of LPS/TLR4 and dsRNA/TLR3. 
TLR4 and TLR3 have the ability to induce type I IFNs and IFN-inducible genes via 
this pathway. TLR4 triggers the MyD88-independent pathway/TRIF-dependent path-
way via another TIR-domain-containing adaptor named TRAM, which associates with 
TRIF and TLR4 (but not with TLR3) working as a bridge between these two molecules 
(28, 37, 38). Activated TRIF transmits a signal to the receptor-interacting protein 1 (RIP-1) 
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which is responsible for the activation of NF-κB (39). In response to TLR4 and TLR3 lig-
ands, TRIF can also activates IKK-related kinases TBK1 and IKK-ε via TRAF3 and these 
kinases directly phosphorylate IRF3 and IRF7 (40, 41), contributing to the activation of 
type I IFNs and IFN-inducible genes (Figure 2).
1.1.3.1.2. TLR3
TLR3 was the first TLR implicated in the sensing of viral nucleic acids. It recognizes 
dsRNA derived from dsRNA virus such as reovirus and dsRNA produced during the 
course of replication of ssRNA virus such as respiratory syncytial virus (RSV), encepha-
lomyocarditis virus (EMCV) and West Nile virus (WNV). Poly(I:C), a synthetic analogue 
of dsRNA, can also mediate responses through TLR3 (42) (Table 1). TLR3 is expressed 
in the endosomal compartments of the immune cells by conventional dendritic cells 
(cDCs) and macrophages, as well as nonimmune cells including fibroblasts, epithelial, 
mesangial and mesothelial cells (43, 44, 45). The stimulation of TLR3 by dsRNA induces 
the activation of the transcription factors nuclear factor (NF)-κB and interferon regula-
tory factor (IRF)/interferon-sensitive response element (ISRE) via MyD88-independent 
signaling pathways, which involves the adaptor molecule TRIF also called TICAM-1 (28, 
46). TLR3 is involved in antiviral host immune responses by producing inflammatory 
cytokines and type I IFNs (Figure 2).
1.1.3.2. RIG-I-like receptors
RLRs comprise a family of cytoplasmic proteins consisting of three members: retinoic 
acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and 
laboratory of genetics and physiology-2 (LGP2). Once TLRs that recognize nucleic acids 
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are localized to endosomes and are unable to recognize virus in the cytoplasm, RLRs 
recognize viral RNAs in the cytoplasm and trigger signaling pathways that induce the 
production of type I IFNs and proinflammatory cytokines (16). 
RIG-I and MDA5 consist of two N-terminal caspase-recruitment domains (CARDs), a 
C-terminal domain and a DExD/H box RNA helicase domain, whereas LGP2 lacks the 
CARD, which is required for triggering intracellular signaling cascades (47) (Figure 3).
1.1.3.2.1. RIG-I
RIG-I, a prototypical member of the RLR family, contains a DExD/H helicase domain, 
which has an ATP-binding motif, and two caspases recruiting-domain (CARD)-like 
domains at its N-terminus. These domains function in interaction with other CARD- 
containing proteins and are required for activating downstream signaling pathways. The 
C-terminal domain contains a repressor domain (RD), which inhibits downstream sig-
nals (48, 49).
In response to detection of viral RNAs, RIG-I recruits an adaptor protein designated IFN-β 
promoter stimulator-1 (IPS-1) [also known as mitochondrial antiviral signaling (MAVS), 
CARD adaptor inducing IFN-β (Cardif) or virus-induces signaling adaptor (VISA)], in a 
CARD-CARD-dependent manner (50). IPS-1 activates IRF3 and IRF7 via TBK1/IKKi 
although it does not directly bind to these protein kinases. TRAF3 binds IPS-1 and 
recruits and activates TBK1/IKKi, which phosphorylate IRF3 and IRF7 (40, 41). Phos-
phorylation of IRF3 and IRF7 induces the formation of homodimers and/or heterodimers 
which translocate into the nucleus and bind to IFN-sensitive response elements (ISREs), 
resulting in the activation of type I IFNs and IFN inducible genes (51) (Figure 3).
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IPS-1 also interacts with FAS-associated death domain-containing protein (FADD), 
which forms a complex with caspase-8 and caspase-10 and this pathway is capable of 
activating NF-κB downstream of IPS-1 (52) (Figure 3). 
A transmembrane domain at the C-terminal end of IPS-1 is required for mitochondrial 
targeting being essential for IRF and NF-κB activation, suggesting that mitochondria 
may somehow be important in antiviral immune responses (53) (Figure 3).
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RIG-I-activated signaling pathway has been implicated in antiviral responses to Sendai 
virus (SeV), vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), as well as 
different flaviviruses and Kaposi’s sarcoma-associated herpes virus (KSHV) (54, 55, 
56). In addition, Chiu and coworkers recently demonstrated that a cytosolic B form of 
dsDNA, poly(dA-dT) ⋅ poly(dA-dT) is able to activate RIG-I and to induce IFN-β produc-
tion via the cytosolic DNA-dependent RNA polymerase III (PolIII) (57).
1.1.3.3. NOD-like Receptors
NOD-like receptors are a family of molecules that detect the presence of PAMPs 
and endogenous molecules within the cytoplasm of cells (24, 58). So far, 23 family 
members have been identified in humans and approximately 34 in mice. These sen-
sors consist of three domains: a c-terminal leucine-rich repeat which is thought to 
be involved in the recognition of microbial PAMPs or endogenous host molecules; 
an N-terminal signaling domain that contains a dead effector domain (DED), a Pyrin 
domain (PyD), a CARD,  baculovirus inhibitor repeats (BIRs) and an acidic domain which 
is required for homotypic interactions with downstream signaling proteins; a central 
nucleotide-binding NACHT domain composed of a CARD, which is required for ligand- 
induced, ATP-dependent oligomerization of the sensors and formation of active recep-
tor complexes for activation of downstream signaling (59, 60). 
Members of NLR includes: NODs (nucleotide-binding oligomerization domain) which 
recognize peptidoglycans, a component of the cell wall of bacteria; NLRC (NLR family, 
CARD domain); NLRPs (contains a Pyrin domain); NLRX1 (NLR family member X1, con-
tain an unknown domain); CIITA (class II, major histocompatibility complex, transactiva-
tor); NAIP (NLR family, apoptosis inhibitory protein) (12) (Table 1).
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1.1.3.4. Inflammasome
The inflammasome is a large multiprotein complex that mediates the activation of inflam-
matory caspases, including caspase-1, which in turn, promotes the proteolytic matura-
tion of the zymogen form of IL-1 family cytokines such as IL-1β and IL-18 (60).
It is assumed that the adaptor protein apoptosis speck-like protein containing a CARD 
(ASC) is required in all inflammasome complexes for procaspase-1 activation. It binds 
to the CARD-containing pro-domain of caspase-1 to mediate its oligomerization and 
subsequent activation (61, 62, 63).
Many viruses are able to activate caspase-1 leading to the production of IL-1β and IL-18. 
Two distinct inflammasome complexes have been described as being involved in antiviral 
immunity: the NLRP3 inflammasome and the AIM2 inflammasome (64, 65, 24) (Figure 4).
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1.1.3.4.1. NLRP3 inflammasome
NLRP3 (also known as NALP3, cryopyrin, cold-induced autoinflammatory syndrome-1 
[CIAS1], CLR1 and PYPAF1) is probably the most widely studied inflammasome so far. 
Its expression is mainly detected in the cytosol of granulocytes, dendritic cells, mono-
cytes, T and B cells, epithelial cells and osteoblasts (66, 67), suggesting an essential 
role in the primary defense mechanism against pathogens.
NLRP3 inflammasome can be activated by numerous PAMPs (viruses, bacteria and 
fungi), DAMPs (danger-associated molecular patterns [heat shock proteins and BCL2]), 
and endogenous molecules such as urate crystals and ATP, bacterial poreforming  toxins 
and particulate matter including silica and asbestos (68, 69, 70, 71) (Table 1). 
NLRP3 inflammasome is composed by NLRP3, ASC and procaspase-1 and its activa-
tion by the appropriate ligands induces caspase-1 activation, which promotes process-
ing of pro-IL-1β and the release of IL-1β after brief stimulation with high concentrations 
of ATP (Figure 5). The CARD of adaptor protein ASC interacts with the CARD of pro-
caspase-1 inducing catalysis of procaspase-1 to yield caspase-1, which catalysis the 
proteolysis of pro-IL-1β	(inactive) to IL-1β (active) (60). 
Several events seem to be required for the activation of NLRP3. This includes: extra-
cellular ATP which activates the purinergic ATP-gated P2X7 receptor which then helps 
to allow the pannexin-1 receptor to cause K+ efflux, being important for NLRP3 inflam-
masome activation; the generation of reactive oxygen species (ROS); lysosomal desta-
bilization after phagocytosis of several crystalline and insoluble ligands, which leads to 
disruption of lysosomal membranes and the release of lysosomal proteins, activating 
NLRP3 inflammasome (72, 73, 74) (Figure 5).
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Although virus recognition mechanisms by NLRP3 inflammasome are still not well 
understood, it was suggested by several groups that NLRP3 further senses infections 
by dsRNA, ssRNA and DNA including Sendai virus, and influenza virus (64, 75, 76).
1.1.3.4.2. AIM2 inflammasome
AIM2 belongs to the HIN-200 family that includes four members in humans (IFI16, MNDA, 
IFIX and AIM2) and six members in mice (IFI202, IFI203, IFI204, IFI205, PYHIN1 and 
AIM2) (77). HIN-200 family contains an amino-terminal pyrin domain (N-terminal PYD) 
and a carboxy-terminal oligonucleotide/oligosaccharide-binding domain (HIN domain). 
AIM2 is a cytoplasmic DNA sensor that directly binds DNA inducing proteolytic acti-
vation of caspase-1 and production and maturation of IL-1β. The HIN domain of AIM2 
binds the DNA while the PYD domain associates with the PYD domain of the adaptor 
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Figure 5. NLRP3 signaling pathway.
Taken from: Int. J. Biochem. Cell Biol. 42, 792–795 (2010).
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molecule ASC, allowing procaspase-1 recruitment, via CARD-CARD interactions, and 
caspase-1 activation with subsequent maturation of IL-1β (24, 78, 79, 80) (Figure 6).
Several studies suggest an important role of AIM2 as a sensor for dangerous cyto-
plasmic DNA and they document the first example of a direct interaction between an 
inflammasome sensor and its ligand. 
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1.1.4.  Type I IFNs and other proinflammatory cytokines 
signaling viral invasion 
All living organisms have developed mechanisms to protect themselves from invasion 
by exogenous pathogens, such as virus. Upon viral infection, the host innate immune 
system has the ability of acting as a first line defense in the prevention of viral invasion 
or replication before the more specific response by the adaptive immune system is 
generated.
After viral recognition, PRRs bind to PAMPs, leading to the activation of transcription 
factors, such as NF-κB, and IFN regulatory factors (IRFs). This event leads to the pro-
duction and secretion of proinflammatory cytokines and type I IFNs (15, 16). 
Cytokines are small cell-signaling molecules produced by cells at the site of infection 
and they are responsible for the first local inflammatory response and some systemic 
effects. There are evidences that during viral replication, the so-called early cytokines 
produced at the site of infection mediate many of the clinical and pathological manifes-
tations. Among these cytokines, interferon-α (IFN-α), tumor necrosis factor-α (TNF-α), 
interleukin-1 (IL-1) α	and β, interleukin-6 (IL-6), interleukin-8 (IL-8/CXCL8) and monocyte- 
attracting chemokines such as MCPs, seem to play an important role in the proinflam-
matory response against the virus (81). Besides being importante for the immediate 
defense, cytokine production also facilitates acquired immunity in several ways: first, 
promotes phagocytosis and antigen presentation by dendritic cells; secondly, proin-
flammatory cytokines, such as IL-1, IL-6 and TNF are co-mitogenic for lymphocytes. 
Some cytokines are similar in their inflammatory effects. IL-1 and TNF are both involved 
in the upregulation of adhesion molecules (E-selectin, ICAM-1, VCAM-1) on vascu-
lar endothelial cells. They are also important to stimulate production of chemotactic 
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cytokines ( chemokines) by connective tissue and endothelial cells (IL-8/CXCL8, MCP-1, 
etc.) and for their stimulating effects on neutrophil and macrophage function. IL-6 is a 
major product of IL-1- or TNF-stimulated cells and has some undeniable proinflamma-
tory features, for example, promoting the fever induced by TNF and IL-1. However, it also 
shows some anti-inflammatory features, such as the capacity to partly downregulate 
TNF production. IL-6 also has major effects on the immune system, activating B cells to 
produce immunoglobulin, and T cells to upregulate some essential receptors (82). 
Although, as it was described above, several cytokines are produced by host cell in 
response to a viral infection, type I IFNs are the principal cytokines involved in the viral 
response. Type I IFNs are represented by multiple isoforms of IFN-α and by IFN-β and 
other members such as IFN-ε, -ω and -κ (83). They can be produced by all nucle-
ated cells in response to a viral infection. Type I IFNs exert their function after binding 
the receptor IFNAR 1/2 and after activation of JAK/STAT signaling pathway (84). IFN 
induction requires the conjugated action of the three transcription factors: ATF2/c-jun 
and NF-κB, which are activated in response to various stimuli such as proinflammatory 
 molecules, and IRF3, which is activated by viral infection (85). 
In a viral infection progress, the production of IFNs increases up to the levels required 
to control virus replication. Since virus replication is controlled, IFN production returns 
to basal levels. For an effective host antiviral response, in addition to a stimulation of 
type I IFNs production that prevents the replication of the virus, it is also necessary an 
attraction of inflammatory cells to the site of infection, which prevents the virus from 
spreading. 
However, viruses have developed strategies to counterattack, finding ways to proliferate 
within host cells. In this sense, viruses have to identify the host targets that are key play-
ers in the antiviral response and find mechanisms to block host molecules that connect 
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virus recognition to downstream effectors of type I IFNs production and inflammatory 
cytokines expression. One example of this is the cleavage of MAVS at its C-terminal end 
by the NS3-4A protease of hepatitis C virus (HCV), which interrupts MAVS interaction 
with the outer mitochondrial membrane, disrupting signal transmission to downstream 
antiviral molecules (i.e. IRF3, IFN-β) and activation of NF-κB (86, 87, 88). The influenza 
virus NS1 protein is also able to antagonize RIG-I/MAVS pathway through the interaction 
of NS1 with the complex, blocking IRF3 activation and IFN-β expression (89). Viruses 
without the ability to suppress the host type I IFN responses are generally low patho-
genic and available for vaccine strains.
1.1.5.  Innate immune recognition and control of adaptive 
immune responses to virus
The immune system of mammals effectively fights infection through the cooperation 
of two connected systems that act together to provide both immediate and long-term 
immunity to pathogens: the innate immune system, which was described before, pro-
vides critical mechanisms for the rapid sensing and elimination of pathogens, and the 
adaptive immune system which is highly specific and is involved in elimination of patho-
gens in the late phase of infection as well as in the generation of immunological memory. 
The interaction between these two arms of immunity enables the immune system to 
efficiently recognize and eliminate invading pathogens with minimal damage to self, and 
provides protection from re-infection with the same pathogen (90).
The innate immune system, by the expression of germ-line encoded receptors (PRRs), 
recognizes viral PAMPs and limits viral replication via type I IFNs production and 
cytokines and chemokines expression, being in most cases enough for the elimination 
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of the pathogen. However, some viral infections outrun the innate immune response and 
when this occurs, the innate immune response works to slow the spread of infection 
while it calls for a stronger and more specific response. In addition to direct activation 
of innate-host defense mechanisms, signals induced by PRRs are also responsible for 
the activation of adaptive immune responses (5). These adaptive immune responses 
demonstrate specificity, discrimination and acquired “memory” for distinct viral mole-
cules and respond more vigorously after repeated exposure to the same viral antigens. 
The adaptive immune responses are mediated by antigen receptors that are clonally 
distributed on the two types of lymphocytes: T cells and B cells (91). The lymphocytes 
and their products coordinate the effector phases of adaptive immune responses and 
may eliminate the virus, primarily by generating neutralizing antibody that is specific for 
the virus and CD8+ cytotoxic T lymphocytes (CTL) that directly kill virally infected cells 
(92). The activation of these cells depends on the induction of co-stimulatory mole-
cules and secretion of cytokines and chemokines by the cells of the innate immune 
system. The key cellular players in translating information from the innate response into 
adaptive immunity are the members of dendritic cell (DC) family (93, 94). Upon infec-
tion, DCs express a repertoire of PRR on their surface and in response to signals from 
these receptors they become antigen-presenting cells (APCs) competent to sustain the 
expansion and differentiation of antigen-specific cells into appropriate effector cells (11). 
When a DC captures a viral antigen, it migrates from the periphery into a secondary 
lymphoid organ, such as the spleen or a lymph node, and presents the viral antigen 
for recognition to naïve CD4+ lymphocytes to promote a T helper type 1 (Th1) immune 
response to the virus. The proliferation and differentiation of naïve CD4+ lymphocytes 
into CD4+ Th1 lymphocytes enables the stimulation of viral antigen-specific B lympho-
cytes and CD8+ lymphocytes to differentiate into plasma cells and cytotoxic T cells 
(CTL), respectively. DCs activated by pathogens normally express high levels of major 
histocompatibility complex (MHC) molecules bearing pathogen-derived peptides, which 
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can engage T cell receptors on naïve pathogen-specific T cells. While CD4+ Th1 lym-
phocytes (that recognize viral antigen presented by MHC class II molecules) are acti-
vated to perform localized effector functions that are designed to eliminate virus at the 
site of antigen encounter, CTL (that recognize viral antigen presented in the context of 
MHC class I molecules) directly kill the cell that presents the viral antigen (92).
In addition to DCs, certain types of nonimmune cells, apart from playing an important 
role in the defense of the host against infection at the front line, can also influence the 
development and direction of the adaptive immune response (9). It is reported that when 
epithelial cells at mucosal sites encounter a microorganism, they produce essential 
chemokines, such as CCL20, that chemoatract immature DCs and inflammatory mono-
cytes to the site of antigen exposure. In addition, ECs also produce critical maturation 
cytokines such as IL-1, GM-CSF, and TSLP that can activate the recruited monocytes to 
differentiate in DCs and induce their maturation into fully competent antigen-presenting 
cells (APCs) that are capable of interacting with naïve T cells, thereby instructing the 
outcome of antigen-specific immunity (95). 
Lamentably, the role of ECs in influencing the development of antigen specific immunity 
against a viral infection is still poorly understood. However, considering the available 
data, it is licit to speculate that ECs, being at the interface between the internal and exter-
nal environment, may be involved in the development of a primary immune response 
against the virus and, probably, be important for the instruction of  antigen-specific 
responses. Nevertheless, future studies are crucial to elucidate this topic.
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1.1.6.  Innate immune response in virus-induced kidney 
diseases
Viral infections are important causes of various kidney diseases often responsible for 
significant morbidity and mortality. In this sense, it is very important to understand how 
infections trigger or aggravate renal pathology. Epstein-Barr virus (EBV), cytomegalo-
virus (CMV), adenovirus, BK virus (BKV), hepatitis-C virus (HCV) and human immuno-
deficiency virus (HIV) infections are commonly associated with specific kidney diseases 
(44, 96). 
Pathogen recognition is not restricted to immune cells and renal cells can also contrib-
ute to this phenomenon. However, the mechanisms involved remain unclear.
The role of innate immune receptors in kidney infections is, so far, largely unknown and 
has been the target of many studies. RNA viruses are highly associated with  kidney 
pathologies. During the course of infection induced by RNA viruses, viral RNA alone 
or as part of immune complexes could reach the mesangium and trigger glomerular 
inflammation. One good example is HCV-associated glomerulonephritis (97). Although 
mesangial cells don’t express TLR7/8, receptors that should be essential for the acti-
vation of these cells by viral ssRNA, previous studies from Wörnle et al. (44) showed a 
robust increase of TLR3 mRNA levels and proinflammatory cytokines and chemokines 
in microdissected glomeruli from biopsies of hepatitis C-associated but not idiopathic 
membranoproliferative glomerulonephritis. In addition, the treatment of cultured mesan-
gial cells with poly(I:C) also resulted in a robust expression of TLR3 and production of 
cytokines and chemokines proposing a role of this receptor in some forms of glomer-
ulonephritis. The activation of mesangial TLR3 during the course of HCV infection can 
also affect the expression of factors, which are relevant for adhesion, mesangial matrix 
metabolisation and fibrosis (98, 99, 100).
48 Activation of innate immune defense mechanisms contributes to polyomavirus BK-associated nephropathy
HIV-associated nephropathy (HIVAN) is also one of the most common causes of chronic 
kidney disease. The primary targets of classical HIVAN are glomerular cells, which typi-
cally show a focal and segmental glomerulosclerosis (FSGS) of the “collapsing type” 
(101). HIV replicates in glomerular cells, however these cells lack TLR7/8, the receptors 
described as being involved in the recognition of viral ssRNA (102). This observation sug-
gests an involvement of receptors other than TLR7/8 in the recognition of HIV in renal cells 
but which receptors and mechanisms are activated during HIVAN are unknown so far.
DNA viruses, such as human herpes virus (HHV), adenovirus or polyomavirus, are also 
commonly associated with renal pathology. CMV or polyomavirus can be an important 
cause of renal allograft nephropathy with the virus replication in tubular epithelial cells. 
During infection by CMV, expression of TLR9 showed to be involved in the activation of 
dendritic cells. In addition, CMV is known to generate RNA transcripts activating den-
dritic cells via TLR3, but the involvement of TLR-independent viral recognition receptors 
to DNA virus remains to be elucidated (103). Also BKV is known to produce dsRNA dur-
ing its replication (42) and recently a study showed the presence of BKV RNA in all BKV 
DNA positive biopsies, indicating an active viral replication, and a possible involvement 
of the dsRNA recognition receptors sensing this virus (104). In this sense, the role of viral 
receptors in the recognition of viral RNA and in the activation of innate immune signals 
during renal infection must be clarified and is the subject of the present study.
1.2. BK virus-associated nephropathy
Polyomavirus-associated nephropathy (PVAN) is an emerging cause of significant 
kidney transplant dysfunction affecting up to 10% of patients, often leading to graft 
loss. Most cases of PVAN are elicited by BK virus (BKV) in the context of intense 
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immunosuppression. Primary BKV infection occurs during childhood, and after infec-
tion the virus persists in the kidney and, upon immunosuppression of the human host, 
causes significant morbidity, particularly in bone marrow and renal transplant patients 
(105, 106, 107, 108). 
BKV belongs to the polyomavirus family along with other five polyomaviruses detected 
in humans: JC virus (JCV), KI virus, WU virus, Merkel cell carcinoma virus, and the 
primate pathogen simian virus 40 (SV40) (109, 110, 111, 112). JCV is associated with 
progressive multifocal leukoencephalopathy, KI virus and WU virus are associated with 
respiratory illness and Merkel cell polyomavirus is associated with Merkel cell carci-
noma. Although most cases of PVAN are due to BKV, JCV has also been implicated in 
a very small percentage (113).
BK virus-associated nephropathy (BKVAN) is by far the most important infectious com-
plication affecting kidney transplants.
1.2.1. Virological and epidemiological aspects of BKV
BKV is a small nonenveloped virus, with a 40- to 44-nm sized icosahedral capsid that 
contains a circular double-stranded DNA genome of 5000-base pair. It encodes for two 
early regulatory proteins — small T antigen and large T antigen — which are involved 
in transformation, viral replication and gene regulation and expression, and three late 
structural capside proteins — viral proteins 1, 2 and 3 (VP-1, VP-2 and VP-3). It also 
encodes for a late protein called agnoprotein, which is probably involved in process-
ing of late mRNAs and assembly of viral particles, and the non-coding control region 
(NCCR), which contains the viral promoters and origin of replication (114, 115, 116).
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The molecular events involved in BKV invasion of host cells and subsequent intracellular 
trafficking are an important area of study. In various cell culture models, BKV uses an 
N-linked glycoprotein containing an alpha(2,3)-linked sialic acid as a receptor and enters 
cells through caveolae-mediated endocytosis (117, 118, 119). After this relatively slow 
and cholesterol-dependent internalization, BKV migrates through the cytoplasm and 
via cellular cytoskeletal components, i.e. the endoplasmic reticulum and microtubules 
to the nucleus, where viral transcription, replication and assembly take place (120, 121) 
(Figure 7). 
BKV is typically acquired during childhood and transmission occurs via oral and res-
piratory routes, but some data suggests transmission via cells and tissues, particu-
larly by kidney transplantation (116, 122). After primary replication, BKV remains in the 
Figure 7. Infectious entry pathway of BKV. 
Taken from: Transpl. Infect. Dis. 8, 62–67 (2006). 
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renourinary tract with intermittent reactivation and low-level DNA load (viruria) in immu-
nocompetent adults (123, 124). The levels of viruria increase in immunocompromised 
individuals often with the presence of decoy cells in urine (125). After kidney transplan-
tation the virus normally replicates in urothelial cells, which remains asymptomatic in 
two-thirds of infected patients (126), but also exhibits tropism for the renal tubular epi-
thelium, where it can establish latent infection (127). Approximately 30%–50% of kidney 
transplant patients with high level viruria progress to BKV viremia (BKV DNA in plasma) 
and the prevalence of BKVAN oscillates between 1% and 10% (128, 129) mostly due to 
immunosuppression treatment and diagnostic methods rather than true differences in 
BKV epidemiology. 
1.2.2. Clinical features and risk factors of BKVAN
The most frequent symptom associated with primary infection by BKV is an upper 
respiratory infection. After primary infection has resolved, the virus remains latent in the 
renourinary epithelium, where viral replication is controlled by mechanisms of immune 
surveillance. BKV tends to persist indefinitely in different organs such as kidney, ureter, 
brain, and lymphoid cells, but changes in immune functions may cause viral reactiva-
tion (130). BKV reactivation is associated to pregnancy, human immunodeficiency virus, 
cancer, diabetes, and transplantation (131, 132).
BKVAN has been recognized as an early event and occurs within the first year after 
transplantation (128, 133). Reactivation of the virus may start as early as 4 months 
post-transplantation and run a course until graft failure with a medium diagnosis time of 
9.5 months (134). The clinical features of BKVAN most closely resemble those of acute 
rejection. Most kidney transplant recipients with BKVAN manifests with renal dysfunction 
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resulting in either an asymptomatic acute or slowly progressive rise in serum creatinine 
concentration (135, 136). The presence of decoy cells in the urine is strongly suggestive 
of polyomavirus infection but they are not entirely sensitive and specific for BKV infection 
(129). BKV DNA is detected in the urine and plasma in nearly all cases of BKVAN (137). 
Occasionally, subjects may show ureteric obstruction and hydronephrosis and cases 
of cystitis have also been reported. 30%–60% of the cases presented with progressive 
renal failure (138). BKVAN is also associated with characteristic histologic findings on 
kidney biopsies (cytopathic changes described posteriorly) (139).
BKVAN was rare until late 1990s and an emergence of the disease became evident 
with the introduction of high doses of new immunosuppressive protocols often includ-
ing mycophenolate mofetil (antiproliferative agent) and tacrolimus (calcineurin inhibitor 
agent) (128, 140, 141, 142). However, some studies suggest that the intensity of immu-
nosuppressors rather than a specific agent is the key risk factor for the emergence 
of BKVAN (143, 144). There are other risk factors that appear to be associated with 
BKVAN. Seronegative subjects who received kidneys from seropositive donors (BKV 
D+/R-) appear to have a higher risk of nephropathy in children (145). Deficient humoral 
and/or cellular immunity may also contribute to structural organ damage and allograft 
dysfunction (146, 147). Recipients with greater donor and recipient HLA mismatching 
appear to have an increase vulnerability to the BKV infection and BKVAN (148). In the 
context of immunosuppression, other risk factors including ongoing graft injury as a 
result of allograft rejection, ischemia, and drug toxicity also have been implicated in the 
development of the disease (149).
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1.2.3. Histological diagnosis of BKVAN
The renal involvement in PVAN is multifocal and distal nephron segments, i.e. medullary 
collecting ducts and distal cortical tubules, are more severely affected than proximal 
segments (150). To achieve a productive infection, the BKV genome has to be delivered 
to the nucleus, where early genes are expressed, followed by DNA replication, late 
protein expression, and virion assembly. Histologically, viral replication results in tubular 
epithelial cell enlargement, karyomegaly and basophilic nuclear inclusion  bodies. These 
cytopathic changes are often associated with lysis of tubular epithelial cells, denuda-
tion of the basement membrane and a strong interstitial inflammatory response, similar 
to that seen in acute rejection (AR). Since this disease is very often misdiagnosed as 
AR, the diagnosis is very difficult but essential. The diagnosis includes detection of 
BKV DNA on urine (viruria) and plasma (viremia) by polymerase chain reaction (PCR) 
or quantitative PCR, presence of “decoy cells” in the urine sediment by urine cytology, 
histopathology of renal allograft biopsies, viral culture, and serology (146, 151, 152, 153, 
154). However, decoy cells, viruria and viremia only indicate viral replication and not 
nephropathy. In this sense the histological diagnosis of BKVAN requires evaluation of a 
renal biopsy with demonstration of cytopathic changes and confirmation with immuno-
histochemical stains for the simian virus 40 (SV40) large T antigen (LT-ag), which identi-
fies all PV infections due to cross-reactivity between SV40 and both the BKV and JCV 
(139) (Figure 8). Distinction between the different types of polyomavirus requires the use 
of species-specific antibodies, in situ hybridization (ISH) or in situ PCR.
Because of the detrimental impact of BKV infection and its association with premature 
graft loss, an early diagnosis is essential to avoid the progression of the disease.
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1.2.4. Histological progression of BKVAN
BKVAN can present with different histological patterns and progress through various 
stages (141, 155, 156, 157, 158). Three histological patterns of BKVAN (A, B and C) can 
be identified in renal biopsies. Pattern A (early changes) corresponds to the early dis-
ease and is characterized by viral cytopathic changes only, in near-normal renal paren-
chyma. The lack of virally induced epithelial cells lysis is typical for this pattern. Negli-
gible or absent tubular atrophy, interstitial fibrosis and inflammation are also features 
Figure 8. : Immunohistochemical staining for SV40 (large T) in human renal biopsies with PVAN 
shows strong nuclear positivity in distal tubular and collecting duct epithelial cells. 
Taken from: Am. J. Trans. 5, 1562–1568 (2005). 
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of this stage of the disease. Pattern B (florid changes) identifies intermediate disease 
and is characterized by combination of viral cytopathic changes and focal/multifocal 
areas of tubular atrophy, interstitial fibrosis and inflammation. Pattern C (late sclerosing 
changes) corresponds to very advanced histological changes and is characterized by 
very scarce cytopathic changes in diffusely scarred renal tissue, and extensive tubular 
atrophy, interstitial fibrosis and inflammation (158, 159).
A progression of pattern A to pattern B or C can be observed if productive viral replica-
tion spreads and virally induced tubular injury persists over weeks to months. A regres-
sion of pattern B to pattern A may be observed during the resolution of BKVAN but 
fibrosis and tubular atrophy in pattern C are irreversible and are associated with severe 
allograft dysfunction or loss (160).
1.2.5. Treatment and prevention of BKVAN
Despite the critical role PVAN may play in long-term graft loss, there is little known about 
the immunology of this infection or its acute or chronic effects on the allograft.
After a renal transplant with an immunologically non-identical kidney almost all recipients 
are submitted to an immunosuppressive therapy in order to prevent acute rejection and 
the loss of the renal allograft. In this situation, an adequate level of immunosuppression 
is required to dampen the immune responses to the allograft. However, to lower the risk 
of infection and malignancy, the level of immunosuppression is slowly decreased over 
time, as the risk of acute rejection decreases. The risk of infection directly correlates 
with the degree of immunosuppression therapy and the intensity of the  therapy must 
also take in consideration the development of chronic allograft nephropathy, which is 
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the most common underlying long-term cause of allograft loss. Currently, the major 
immunosuppressive agents being used in various combination regimens are: corti-
costeroids (prednisone), antiproliferative agents (azathioprine, mycophenolate mofetil), 
 calcineurin inhibitors (tacrolimus, cyclosporine), and mammalian target of rapamycin 
inhibitors (mTOR [sirolimus, everolimus]) (Table 2) (161, 162, 163).
Treatment of BKVAN is still evolving and, as the optimal maintenance immunosuppres-
sive therapy is still not well established, the best treatment so far is an early diagnosis 
of the disease in order to act before renal damage is caused. The first-line treatment 
of BKVAN is the reduction of the immunosuppression (106, 116, 164) but current evi-
dences suggest that prevention based upon a screening and preemptive strategy is 
superior to an approach that relies upon therapy of established disease (165). 
Given the frequency of polyomavirus infection and the potential for graft loss,  randomized 
trials of treatment and prevention strategies are absolutely needed to better guide thera-
 py and improve outcomes for kidney transplant patients with BKVAN.
1.2.5.1. Treatment
Many studies are being developed in order to find effective treatment for BKVAN and at 
the same time to reduce the risk of rejection and to preserve renal function. The main-
stay of therapy for BKVAN in kidney transplant recipients is to improve BKV-specific 
immunity by reducing or discontinuing immunosuppressive drugs (166). Several strate-
gies and their combinations have been reported in the context of immunosuppressive 
 therapy in patients with definitive diagnosis of nephropathy. One of the strategies involves 
first the reduction of the calcineurin inhibitor (tacrolimus or cyclosporin) by 25%–50%, 
followed by the reduction of the antiproliferative agent (MMF or azathioprine) by 50% or 
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discontinuation of the last if viremia persists (135, 167, 168) (Figure 9). Another strategy 
is based in the reduction of the antiproliferative agent by 50% followed by the reduction 
of calcineurin inhibitor by 25%–50% followed by discontinuation of the antiprolifera-
tive agent if necessary (168, 169) (Figure 9). A substitution of the calcineurin inhibitor 
tacrolimus by a lower dose of cyclosporine or switching from calcineurin inhibitor to 
low-dose of sirolimus (mTOR agent) can also be an effective additional strategy. Steroid 
(prednisone) avoidance has also been suggested to decrease the prevalence of BKVAN 
(170). The reduction of immunosuppression strategy can also be considered for patients 
with presumptive BKVAN defined by sustained viremia (104 copies/mL) for more than 
three weeks. The protocol appears to be safe and effective for preventing BKVAN and 
clearing BKV viremia with low rates of acute rejection (144). Few reports suggest the 
use of adjuvant drugs such as cidofovir, leflunomide, intravenous immunoglobulin (IVIG) 
or fluoroquinolones in combination with immunosuppression reduction in patients with 
sustained high-level of plasma BKV load (171, 172). However, larger randomized control 
trials proving that adjunctive use of these agents with antiviral activity is superior over 
timely reduced immunosuppression are still missing.
1.2.5.2. Prevention strategies
A screening and preemptive strategy is based in the idea that periodic monitoring of 
viruria (Vr) and viremia (Vm) allows the detection of early systemic infection, which per-
mits a prompt treatment including a decrease of immunosuppression and/or adminis-
tration of antiviral agents, and may limit morbidity and mortality (129, 158). The appear-
ance of BK Vr is a characteristic that precedes the development of BKVAN, reflecting 
viral activation and replication in the renourinary tract. However, BK Vr is not by itself 
diagnostic of renal parenchymal involvement. In contrast the identification of BK Vm is 
pathognomonic of renal parenchymal disease and allows a diagnosis of presumptive 
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BKVAN (164). Higher prevalence of Vr, as opposed to Vm, and lack of good correlation 
with Vr induced investigators to use Vm as a better marker for preemptive reduction in 
immunosuppressive therapy (136). 
Current guidelines for the screening and diagnosis have been published (128, 168). 
Screening for BKV replication must be performed at least every three months, for up 
to two years post-transplant and then annually until the fifth year post-transplant (128). 
BKV replication in the urine (Vr) can be studied either by cytology for decoy cells or by 
quantitative PCR for BKV DNA or VP1 mRNA (128, 137, 156, 168, 173, 174). Patients 
with a positive screening test (decoy cells or urine DNA load greater than 107 copies/
mL) should be tested for plasma BKV DNA load (Vm). In patients with plasma DNA 
load greater than 104 copies/mL and persistent for more than three weeks, an allograft 
biopsy should be considered to definitively diagnose BKVAN (128, 168) (Figure 9). Vigor-
ous post-transplantation screening and preemptive strategies allows the identification of 
patients at risk for BKVAN before significant parenchymal damage occurs by the detec-
tion of the disease at an early stage, and improves graft survival of patients with BKVAN.
Table 2. Immunosuppressive drugs used in kidney transplantation (162)
Group Drug Mechanisms
Calcineurin inhibitors Cyclosporine
Tacrolimus
Binds to cyclophilin; complex inhibits cal-
cineurin phosphatase and T cell activation
Binds to FKBP12; complex inhibits calcineurin 
phosphatase and T cell activationn
Antiproliferative agents Mycophenolate 
mophetil
Azathioprine
Inhibits synthesis of guanosine monophos-
phate nucleotides; blocks purine synthesis, 
preventing proliferation of T and B cells
Converts 6-mercaptopurine to tissue inhibitor 
of metalloproteinase, which is converted to 
thioguanine nucleotides that interfere with 
DNA synthesis; thioguanine derivates may 
inhibit purine synthesis
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Corticosteroids Prednisone Inhibits T cell activation with subsequent pre-
vention of T cells from attacking the trans-
planted organ
Mammalian target of 
rapamycin inhibitors 
(mTOR)
Sirolimus
Everolimus
Binds to FKBP12; complex inhibits target of 
rapamycin and interleukin-2-driven T cell 
proliferation
Derivate of sirolimus
Figure 9. Screening and treating BKV replication and disease in kidney transplant patients. 
Taken from: Am. J. Transplant. 9, S136–S146 (2009). 
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1.2.6.  Polyomavirus BK and the activation of innate immune 
defense mechanisms leading to BKVAN
For polyomavirus BK, dsDNA and dsRNA are critical targets. The dsRNA is a molecular 
pattern associated with viral infection because most viruses at some point produce it 
during their replication cycle (42, 175). In this study, we restricted our search for receptors 
that could be involved in PVAN to those that sense nucleic acids in the cytoplasm and 
endosomal compartments. Among the several intracellular dsRNA sensors described 
above, TLR3 and RIG-I seem to be good candidates to play an essential role in PVAN. 
TLR3 recognizes viral dsRNA, which is generated during life cycle of many virus, and 
its synthetic analogue poly(I:C) through its unique adaptor protein TRIF (28, 176, 177). 
Recognition of viral RNA by TLR3 triggers activation of the transcription factors NF-κB 
and IRF3 and induction of type I IFNs, which are critical for cellular antiviral responses. 
RIG-I is a highly inducible cytoplasmic RNA helicase that signals antiviral responses 
after binding dsRNA and ssRNA containing a 5`triphosphate (5`-ppp). This pathway has 
been implicated in antiviral responses to Sendai virus,  vesicular stomatitis virus, New-
castle disease virus, as well as different  flaviviruses and Kaposi’s sarcoma-associated 
herpesvirus (54, 55, 56) and the cytosolic B form of dsDNA, poly(dA-dT) ⋅ poly(dA-dT) 
via the cytosolic DNA-dependent RNA poly merase III (PolIII) (57).
Because of the characteristics involved in BKV invasion of host cells and subsequent 
intracellular trafficking we hypothesized that particularly TLR3 could be a recep-
tor candidate to mediate activation of innate immunity in PVAN. First, TLR3 resides 
in the endosomal membrane and the endoplasmic reticulum and moves to dsRNA- 
containing endosomes in response to dsRNA (178). As BKV has previously been shown 
to enter cells through endocytosis, viral dsRNAs could activate TLR3 during BKV infec-
tion of tubular epithelial cells upon viral entry and uncoating in the endosome. Sec-
ond, upregulation of the TLR3 pathway was reported in response to various viruses 
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containing a dsDNA genome: KSHV upregulates TLR3 expression in human mono-
cytes during primary infection (179); TLR3 can control herpesvirus infection, since chil-
dren with a TLR3 deficiency were very susceptible to HSV-1-induced encephalitis (180); 
Infection of a neuron cell line with HSV-1 triggers IL-6 and IRF1 mRNA production (181). 
In addition, in a mouse model of murine CMV infection, the TLR3-mediated TRIF sig-
naling pathway is activated on viral inoculation, contributing to innate defense against 
systemic viral infection (103).
In this study, we examined the activation of TLR3 and RIG-I in allograft biopsy samples 
of PVAN and in human collecting duct epithelial cells after poly(I:C) and cytokine stimu-
lation, as well as after infection with BKV. Our findings indicate that activation of innate 
immune defense mechanisms, that is, TLR3, contributes to the inflammation in PVAN.
In summary, the detailed immunopathogenesis as well as specific pathways acti-
vated during the viral infection of the kidney leading to significant inflammatory glo-
merular and tubulointerstitial injury are poorly understood. In particular, the role of the 
innate immune system, the function of Toll-like receptors, in particular TLR3, and the 
involvement of the recently identified IFN-induced RNA helicases (RIG-I and MDA5) 
and oligomerization domain (NOD)-like receptors, sensing the presence of viral dsRNA 
remain to be fully elucidated. To study the molecular and cellular pathways initiated 
in the PVAN was, therefore, the goal of this current research project. The identifica-
tion of specific signaling cascades activated during the viral infection of renal cells 
should allow us to identify new target molecules for a specific antiviral and anti- 
inflammatory therapy in this disorder.
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2. Objectives
As PVAN is a significant complication after kidney transplantation, which can often lead 
to graft dysfunction and may cause morbidity and even mortality, and innate immune 
system has a critical role in recognizing viral infections and evoking initial antiviral 
responses, the aim of this study was to identify antiviral responses of the renal tubular 
epithelium during the course of this pathology. For this, we studied:
 • The activation of TLR3 and RIG-I in allograft biopsy samples of PVAN and in human 
collecting duct epithelial cells after poly(I:C) and cytokine stimulation as well as after 
infection with BKV;
 • The activation of proinflammatory cytokines and type I IFNs produced downstream 
TLR3 and RIG-I;
 • The BK virus–host cell interaction and the activation of signaling cascades leading 
to renal inflammation.

CHAPTER 3
MATERIALS AND METHODS

69Chapter 3 — Materials and Methods
3. Materials and Methods
3.1. Materials
3.1.1. Equipments and instruments
Balances:
 • Analytical Balance, BP 110 S (Sartorius, Göttingen, Germany)
Cell Incubators:
 • Type B5060 EC-CO2 (Heraeus Sepatech, München, Germany)
Centrifuges:
 • Heraeus, Megafuge 1.0R (Thermo Scientific, Langenselbold, Germany)
 • Hettich Zentrifugen, Rotante 460 R (Hettich Zentrifugen, Adelsried, Germany)
 • Hettich Zentrifugen, Universal 16 (Hettich Zentrifugen, Adelsried, Germany)
 • Eppendorf, Centrifuge 5415 D (Eppendorf, Hamburg, Germany)
ELISA-Reader:
 • Tecan, GENios Plus (Tecan, Crailsheim, Germany)
Spectrophotometer:
 • Beckman DU® 530 (Beckman Coulter, Fullerton, CA, USA)
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TaqMan Sequence Detection System:
 • ABI prism ™7700 sequence detector (PE Biosystems, Darmstadt, Germany)
Microscopes:
 • Leica SP5 (Leica Microsystems, Solms, Germany)
3.1.2. Other equipments
 • Thermomixer 5436 (Eppendorf, Hamburg, Germany)
 • Vortex genie 2™ (Bender&Hobein AG, Zurich, Switzerland)
 • Water bath HI 1210 (Leica Microsystems, Bensheim, Germany)
3.1.3. Chemicals and reagents
Cell culture:
 • Dulbeccos’s Modified Eagle’s medium (GIBCO/Life technologies, Paisley, Scotland, 
UK)
 • Ham’s F12 medium (GIBCO/Life technologies, Paisley, Scotland, UK)
 • Insulin (Sigma-Aldrich, Steinheim, Germany)
 • Dexamethasone (Sigma-Aldrich, Steinheim, Germany)
 • Sodium Selenite (Sigma-Aldrich, Steinheim, Germany)
 • Transferrine (Sigma-Aldrich, Steinheim, Germany)
 • L-Glutamine (GIBCO/Life technologies, Paisley, Scotland, UK)
 • Hepes Buffer (GIBCO/Life technologies, Paisley, Scotland, UK)
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 • Heat-inactivated Fetal Bovine Serum (Biochrom KG, Berlim, Germany)
 • Dulbecco’s PBS (1x) (PAA laboratories, Cölbe, Germany)
 • Trypsine/EDTA (1x) ( PAA laboratories, Cölbe, Germany)
 • Penicillin/Streptomycin (PAA laboratories, Cölbe, Germany)
Stimulation experiments:
 • Poly(I:C) (Invivogen, San Diego, CA, USA)
 • Poly(dA:dT) (Sigma-Aldrich, Steinheim, Germany)
 • TNF-α ( PeproTech, Hamburg, Germany)
 • IL-1β (PeproTech, Hamburg, Germany)
 • IFN-α (PeproTech, Hamburg, Germany)
 • Opti-MEM I medium (GIBCO/Life technologies, Paisley, Scotland, UK)
 • Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany)
Molecular biology techniques:
 • PureLink RNA Mini Kit (Invitrogen, Karlsruhe, Germany)
 • RNase free DNase (Qiagen, Hilden, Germany) 
 • Superscript II ( Invitrogen, Karlsruhe, Germany)
 • Hexanucleotide Mix (Roche, Mannheim, Germany)
 • Recombinant RNasin Ribonuclease inhibitor (Promega, Mannheim, Germany)
 • dNTP Set ( Fermentas, St. Leon-Rot, Germany)
 • Acrylamide (Ambion, Tokyo, Japan)
 • 5 × buffer (Invitrogen, Karlsruhe, Germany)
 • DTT (Invitrogen, Karlsruhe, Germany)
 • Qubit RNA assay Kit ( Invitrogen, Karlsruhe, Germany)
 • RT-PCR primers (Applied Biosystems, Darmstadt, Germany)
 • DC protein assay kit (Bio-Rad Laboratories, Munich, Germany)
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 • Western Lightning Chemiluminescence reagent plus Kit (PerkinElmer, Massachu-
setts, USA)
ELISA Kits:
 • Human IL-6 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA)
 • Human CXCL8/IL-8 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA)
 • Human IL-1β/IL-1F2 Quantikine HS ELISA kit (R&D Systems, Minneapolis, MN, USA)
 • Human IFN-β ELISA Kit ( PBL Interferon Source, New Jersey, USA)
Antibodies:
 • Human TLR3 antibody (Acris Antibodies, Herford, Germany) 
 • Human RIG-I antibody (provided by Dr. Simon Rothenfusser (182))
 • Human IL-1β/IL-1F2 antibody (R&D Systems, Minneapolis, MN, USA)
 • Rabbit anti-mouse IgG [H&L]-HRP (Acris Antibodies; Hiddenhausen, Germany)
 • Goat anti-rat IgG+IgM [H+L] (Jackson ImmunoResearch Laboratories, Inc.; West 
Grove, PA, USA)
 • Rabbit anti-goat IgG Peroxidase conjugate (Calbiochem, San Diego, CA, USA)
 • Rabbit polyclonal to beta-Actin (Abcam, Cambridge, UK)
 • Goat anti-rabbit IgG Peroxidase Conjugate (Calbiochem, San Diego, CA, USA)
 • Mouse anti-T-Ag (Calbiochem, San Diego, CA, USA)
Knockdown experiments:
 • siPort NeoFX Transfection Agent (Ambion, Tokyo, Japan)
 • Pre-designed siRNA for TLR3 or RIG-I (Ambion, Tokyo, Japan)
 • Silencer negative control siRNA (Ambion, Tokyo, Japan)
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3.1.4. Other Chemicals
 • Bovine Serum Albumin (Roche Diagnostics, Mannheim, Germany)
 • DMSO (Merck, Darmstadt, Germany)
 • EDTA (Calbiochem, San Diego, USA)
 • Ethanol (Merk, Darmstadt, Germany)
 • Isopropanol (Merk, Darmstadt, Germany)
 • Mercaptoethanol (Roth, Karlsruhe, Germany)
 • Trypan blue (Sigma, deisenhofen, Germany)
3.1.5. Miscellaneous
 • Accu-jet Pro Pipette controller (Brand, Wertheim, Germany)
 • Pipette’s tip 1-1000 µl (Eppendorf, Hamburg, Germany)
 • PVDF membrane (Millipore Immobion, Schwalbach, Germany)
 • Tissue culture flasks 15 and 75 cm² (TPP, Trasadingen, Switzerland)
3.2. Methods
3.2.1. Preparation of human tissue
For mRNA expression analysis, parts of human renal biopsies were obtained according 
to the local ethical committees directives and samples were processed according to 
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the protocol of an European multicenter study for gene expression analysis (the Euro-
pean Renal cDNA Bank — Kroener-Fresenius Biopsy Bank, ERCB-KFB) (183). Micro-
dissected tubulointerstitial specimens from 21 patients were analyzed, including 10 allo-
graft biopsies with acute cellular rejection and 5 allograft biopsies with PVAN. In both 
groups the Banff histologic scores and the immuno-histochemical analysis of inflamma-
tory infiltrates were similar. For control biopsies, renal tissue was derived from pretrans-
plantation kidney biopsies during cold ischemia time from three cadaveric (CON CDx, 
n=3) and three living donors (CON LDx, n=3). 
For double immunofluorescence staining, paraffin-embedded tissue sections from 
a total of 23 renal allografts including 19 cases with a histological secured diagno-
sis of PVAN and 4 randomly chosen transplant biopsies with AR were obtained from 
the Department of Cellular and Molecular Pathology at the German Cancer Research 
Center following guidelines of the respective Ethics Committees.
3.2.2.  Immunofluorescence technique for TLR3 and SV40 
double staining 
For immunofluorescence double staining, kidney needle biopsies from patients with 
PVAN were fixed and embedded in paraffin. 5 μm sections were prepared and mounted 
on glass slides. After microwave antigen retrieval with citrate buffer, the specimens 
were treated with blocking buffer and subsequently with primary antibodies against 
SV40 ((1:20) mouse T Antigen) or TLR3 ((1:100) anti-human guinea pig), followed by 
species-specific secondary antibodies as described (184). Specimens were analyzed 
on a Leica SP5 confocal microscope and confocal stacks were modeled using Volocity 
software (Waltham, MA). 
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3.2.3. Cell culture and stimulation experiments
3.2.3.1.  Cell culture of immortalized human collecting duct epithelial 
cells (HCDCs)
Immortalized human cortical collecting duct epithelial cells (HCDCs) were provided by 
H. Debiec (185). Cell line was maintained under standard cultural conditions (in an incu-
bator set at 37°C supplied with 5.0% CO2) in culture medium containing a 1:1 mixture of 
Dulbecco’s Modified Eagle’s medium and Ham’s F12 medium supplemented with 5 µg/
ml Insulin, 5 × 10-8 M Dexamethasone, 3 × 10-8 M Sodium Selenite, 5 µg/ml Transferrine, 
2 mM Glutamine, 10 M HEPES Buffer and 2% heat-inactivated fetal bovine serum. 
3.2.3.2. Stimulation experiments
Extracellular poly(I:C) or cytokine stimulation of HCDCs
For stimulation experiments, HCDCs were plated in culture six-well plates one day 
before the experiment. For ELISA and RNA extraction, cells were incubated with 
medium control or a combination of TNF-α (25 ng/ml), IL-1β (10 ng/ml) and IFN-γ 
(20 ng/ml) for 24 h, washed with PBS, incubated in culture medium for 6 hours and 
washed again with PBS. Subsequently, HCDCs were incubated with medium con-
trol or medium containing poly(I:C) (10 µg/ml) for 12 h. After the incubation period, 
aliquots of the supernatant medium were removed for ELISA analysis at the times 
indicated and cells were washed with PBS and prepared for RNA isolation.
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Intracellular poly(I:C) or poly(dA:dT) transfection in HCDCs
24 h before transfection, cells were plated in a culture 6-well plate in 2 ml growth 
medium. To examine the effect of poly(I:C) or poly(dA:dT) intracellularly, HCDCs were 
treated with medium control or transfected with poly(I:C) (5 µg/ml) or poly(dA:dT) 
(5 µg/ml) in different time intervals (3, 6, 9, 12 and 24 h) using Lipofectamine 2000. 
After stimulation, cell supernatants were collected for ELISA and cells were washed 
with PBS and prepared for RNA isolation
BKV infection
For infection of the cells, virus prepared previously was dissolved in culture medium 
and 1 ml was added to HCDCs that were plated 24 h before. Cells were incubated 
with medium alone (control) or medium containing the virus for different time inter-
vals (3, 6, 9, 12 and 24 h). After each time point, corresponding supernatants were 
collected for ELISA analysis and cells were prepared for RNA isolation.
3.2.4. RNA isolation, cDNA synthesis and real-time RT-PCR 
3.2.4.1. RNA isolation from cultured cells
After stimulation with the combination of cytokines and/or poly(I:C) or poly(dA:dT), RNA 
isolation was performed using a RNeasy Mini Kit, according to the manufacture protocol. 
Cells were washed with PBS to remove residual medium and 350 µl of RLT buffer (lysis 
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buffer) containing 1% β-mercaptoethanol were added to the cells. Cells were scraped 
and immediately transferred to microcentrifuge tubes and frozen at -80°C until RNA isola-
tion. For RNA isolation, cell lysates were thawed and 350 µl of 70%  ethanol were added. 
The mixture was mixed well by pipetting to blend thoroughly and to disperse any visible 
precipitate that may form after adding ethanol. This mixture was transferred to RNeasy 
mini-columns held in 2 ml collection tubes and centrifuged for 15 s at 10000 rpm. The 
flow-through was discarded and 350 µl of RW1 buffer (washing membrane-bound RNA 
buffer) were added to the column and centrifuged again for 15 s at 10000  rpm. After 
discarding the flow-through RNase-free DNase was added to the samples for an efficient 
on-column digestion of DNA during RNA purification. After 15 min incubation at room 
temperature, 350 µl of RW1 buffer were added again to the column and centrifuged 15 s 
at 10000 rpm. The flow-through was discarded together with the collection tubes and 
the column was transferred in new 2 ml collecting tubes. 500 µl of RPE buffer (washing 
membrane-bound RNA buffer) were added to the column and centrifuged for 15 s at 
10000 rpm and the flow-through was discarded. This step was once again repeated. The 
column was placed in a new 1.5 ml collection tube, 35 µl of RNase free water were added 
to the column and centrifuged for 1 min at 10000 rpm to elute the RNA.
3.2.4.2. Complementary DNA synthesis 
The RNA samples isolated according to the procedure detailed above were diluted in 
DEPC water (1 µg/30 µl) and a mastermix containing 9 µl of 5 × buffer, 1 µl of 25 mM dNTP 
mixture, 2 µl of 1.1 M DTT, 1 µl of 40U/µl RNasin, 0.5 µl of 15 µg/ml acrylamide, 0.5 µl of 
hexanucleotides and 1 µl of superscript (or ddH2O in case of the negative controls) was 
prepared. 15 µl of mastermix were added to each RNA sample and incubated at 42°C 
on a thermal shaker incubator for 90 min. After incubation, cDNA samples were collected 
and stored at -20°C. For real-time RT-PCR samples were diluted for 10 times in ddH2O.
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3.2.4.3.  Quantitative real-time reverse transcriptase-polymerase 
chain reaction (RT-PCR) analysis
Real-time RT-PCR analysis was performed on a TaqMan ABI 7700 sequence detection 
system using heat-activated TaqDNA polymerase. After an initial hold of two minutes 
at 50°C and ten minutes at 95°C, the samples were cycled 40 times at 95°C for 15 
seconds and 60°C for 60 seconds. For all quantitative analyses the cDNA content of 
each sample was compared with another sample following the ΔΔCt technique. This 
procedure uses the formula A0/B0 = (1 + E)
(Ct,B–Ct,A), where A0 is the initial copy number of 
sample A; B0 is the initial copy number of sample B; E is the efficiency of amplification; 
Ct,A is the threshold cycle of sample A; and Ct,B is the threshold cycle of sample B. 
The amplification efficiency was defined as 1, as all analyses were performed during 
the same run, including control dilution series. Following the formula above, the cDNA 
content of sample A compared to sample B was calculated by subtracting the mean Ct 
(triplicates) of sample A from the mean Ct of sample B (= ΔCt). Copies of the individual 
transcripts in sample A were defined as 2ΔCt copies of transcripts in sample B. 
Commercially available predeveloped TaqMan reagents were used for the human target 
genes TLR1-8, TLR10, RIG-I, IL-6, RANTES/CCL5, MCP-1/CCL2, IL-8/CXCL8, IFN-β, 
IP-10/CXCL10, IL-1β, NLRP3, AIM2, caspase-1, TRIF and two endogenous control genes 
(18S rRNA, GAPDH) (Table 3). For human TLR9 detection a primer pair was used:  forward 
primer: 5`-CGGAGGCTGGATGTCAGC-3`; reverse primer: 5`-GGAGTGGTCCACT 
GTCTTGAGG-3`; specific probe: 5`-AGCTGCGAGAGCTCAACCTTAGCGC-3`; FAM and 
TAMRA labeled. For detection of BKV Large T-antigen sequence, the following primer 
pair was used: forward primer: 5`-GGAAAGTCTTTAGGGTCTTCTACCTTT-3`; reverse 
primer: 5`-GGTGCCAACCTATGGAACAGA-3`; specific probe: 5`-AATCTGCTGTTGCT 
TCTTCATCACTGGCA-3 ,` VIC and TAMRA labelled. The normalization to both reference 
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(housekeeping) genes gave comparable results. All measurements were performed in 
duplicates. Controls consisting of bidistilled H2O were negative in all runs. 
Table 3. Taqman gene expression assays used in the study
Gene Accession 
number
Assay ID Context Seq AoD
IL-6 NM_000600 Hs00174131_m1 TGGATTCAATGAGGAGACTTGCCTGGTGAA
RANTES/
CCL5
NM_002985.2 Hs00174575_m1 TCCAACCCAGCAGTCGTCTTTGTCACCCG
MCP1/
CCL2
NM_002982.3 Hs00234140_m1 TCAGCCAGATGCAATCAATGCCCCA
IL-8/CXCL8 NM_000584.2 Hs00174103_m1 GCTCTGTGTGAAGGTGCAGTTTTGCCAAG
IP-10/
CXCL10
NM_001565.2 Hs00171042_m1 GTGGCATTCAAGGAGTACCTCTCTCTAGAAC
IFN-β NM_002176.2 Hs00277188_s1 TACCTCCGAAACTGAAGATCTCCTAGCCT
TLR3 NM_003265.2 Hs00152933_m1 TAGCAGTCATCCAACAGAATCATGAGACAG
RIG-I NM_014314.3 Hs00204833_m1 CCCTAGACCATGCAGGTTATTCTGGACTTT
IL-1β NM_000576.2 Hs00174097_m1 TGGAGCAACAAGTGGTGTTCTCCATG
NLRP3 NM_183395.2
NM_001079821.2
NM_001127462.2
NM_001127461.2
NM_001243133.1
NM_004895.4
Hs00918082_m1 GAGCCGAAGTGGGGTTCAGATAATG
AIM2 NM_004833.1 Hs00175457_m1 GATCAGGAGGCTGATCCCAAAGTTGTCA
Caspase-1 NM_001223.4
NM_001257118.1
NM_00125719.1
NM_033292.2
NM_033293.2
NM_033294.2 
NM_033295.2
Hs00354836_m1 CCGCAAGGTTCGATTTTCATTTGAG
TRIF NM_182919.2 Hs01090712_m1 GCAGCCCCGGATCCCTGATCTGCTT
TLR1 NM_030956.3 Hs00374069_g1 TTGAAACTTCCATCTGTAAGGCTAT
TLR2 NM_003264.3 Hs00152932_m1 TGGTAGTTGTGGGTTGAAGCACTGG
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TLR4 NM_003266.3 Hs00370853_m1 CTGCGTGGAGACTTGGCCCTAAACC
TLR5 NM_003268.5 Hs00152825_m1 ACAGTCACCAAACCAGGGATGCTAT
TLR6 NM_006068.4 Hs00271977_s1 CCAGCTACTTGATTTAAGTGTTTTC
TLR7 NM_016562.3 Hs00152971_m1 GACTAAAAATGGTGTTTCCAATGTG
TLR8 NM_016610.2 Hs00152972_m1 GGAAAGGAGACTAAAAAGGAAAACA
TLR10 NM_030956.3 Hs00374069_g1 TTGAAACTTCCATCTGTAAGGCTAT
GAPDH NM_002046.3 4310884E
18S rRNA X03205.1 4310893E
3.2.5.  Fluorescence-activated cell sorting (FACS) analysis  
for TLR3
HCDCs were cultured under basal conditions for 24 h. For FACS analysis cultured cells 
were detached with PBS/10 mM EDTA (pH 8) and incubated for 30 min on ice with 
a monoclonal antibody against TLR3 or the appropriate isotype controls. After two 
washing steps with PBS, cells were incubated with a fluorescein isothiocyanate (FITC) 
rabbit secondary antibody against mouse F(ab)2 fragment and incubated on ice for 
30 min. After washing the cells twice with PBS, the tubes were centrifuged for 2 min 
at 1200 rpm and finally the pellet was suspended in 200 µl of PBS and FACS analysis 
was carried out. For intracellular staining, HCDCs were treated with Cytofix/Cytoperm 
Reagent followed by monoclonal antibody against TLR3 and secondary antibody incu-
bations in saponin buffer. The TLR3 signal was analyzed using a FACSCalibur with 
CellQuest analysis software. Appropriate IgG isotype preparations (mouse IgG1 clone 
MOPC 21) were used to control for unspecific staining.
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3.2.6.  Western immunoblot analysis for TLR3, RIG-I  
and IL-1β
After incubation with poly(I:C) or poly(dA:dT) with or without prestimulation with proin-
flammatory cytokines, HCDCs were lysed with RadioImmunoPrecipitation assay (RIPA) 
buffer (50 mM Tris-HCL, pH 8; 150 mM NaCl; 1% NP-40; 0,5% Sodium Deoxycholate; 
0,1% SDS) containing protease inhibitors. The lysates were cleared by centrifugation at 
13.000 X g for 15 min at 4°C and protein concentration was determined with DC protein 
assay kit. Proteins (40 µg/ml) were separated by sodium dodecyl sulphate-polyacryla-
mide (SDS-PAGE) on an 8% polyacrylamide gel and transferred to a PVDF membrane 
for western blotting. The membranes were blocked in 3% milk solution in Tris-buffered 
saline-Tween 20 (TLR3) or 5% Bovine Serum Albumin (RIG-I, IL-1β, beta-Actin loading 
control) for 1 h and probed overnight with a monoclonal antibody against human TLR3 
or human RIG-I or human IL-1β.
After washing four times in TBST (Tris-buffered saline-Tween 20), the membranes were 
incubated with secondary purified rabbit anti-mouse IgG [H&L]-HRP (TLR3) or second-
ary peroxidase-conjugated AffiniPure goat anti-rat IgG+IgM [H+L] (RIG-I) or anti-goat 
IgG peroxidase conjugate (IL-1β) for 1 h and washed again four times with TBST. Signals 
were visualized with a Western Lightning Chemiluminescence reagent plus Kit.
Beta-Actin was used as a loading control and the secondary antibody was an anti- 
rabbit IgG Peroxidase conjugate.
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3.2.7. ELISA
ELISA for IL-6, IL-8/CXCL8, IL-1β and IFN-β were performed on cell culture supernatants 
using commercial assay kits and according to the supplied instructions. 
For IL-6 and IL-8/CXCL8, 100 µl of Assay Diluent were added to each well. Next, 100 µl 
(IL-6) or 50 µl (IL-8/CXCL8) of standard, sample or control were added per well and the 
plate was incubated for 2 h at room temperature. After the incubation time, each well 
was washed four times with 400 µl of Wash Buffer followed by the complete removal of 
the liquid. 200 µl (IL-6) or 100 µl (IL-8/CXCL8) of Conjugate solution was added to each 
well and the plate was incubated again for 2 h (IL-6) or 1 h (IL-8/CXCL8) at room tem-
perature. After the incubation time, the wells were washed again four times with 400 µl 
of Wash Buffer and this was followed by the complete removal of the liquid. 200 µl of 
Substrate solution were added to each well and the plate was incubated for 20 min (IL-6) 
or 30 min (IL-8/CXCL8) at room temperature and protected from light. 50 µl of the Stop 
solution were then added to each well and the optical density of each well was deter-
mined using a microplate reader set to 450 nm with a wavelength correction of 570 nm. 
The results were determined by calculating the average of the duplicate readings for 
each standard, control and sample. A standard curve was created by plotting the mean 
absorbance for each standard on the y-axis against the concentration on the x-axis and 
drawing a best curve through the points on the graph.
For IL-1β, 100 µl of Assay Diluent were added to each well followed by 150 µl of stand-
ard, sample or control. The plate was incubated for 3  h at room temperature on a 
horizontal orbital microplate shaker set at 500 rpm. After the incubation time, the wells 
were washed six times with 400 µl of Wash Buffer followed by the complete removal of 
the liquid. Next, 200 µl of Conjugate solution were added to the wells and the plate was 
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incubated for 2 h at room temperature on the shaker. After the incubation time, 50 µl 
of Substrate solution were added to each well and the plate was incubated again for 
30 min at room temperature and on the shaker. 50 µl of Amplifier solution were added 
to each well followed by a new incubation period of 30 min at room temperature on the 
shaker. Finally, 50 µl of Stop solution were added to the wells and the optical density 
of each well was determined at 490 nm with a wavelength correction of 690 nm. The 
results were determined as described above.
For IFN-β, 100 µl of interferon standards, blanks and samples were added to the each 
well and the plate was incubated for 1 h at room temperature. After 1 h the wells were 
washed three times with 300 µl of diluted Wash Buffer. Next, 100 µl of diluted antibody 
solution were added to all wells and the plate was incubated for 1 h at room temper-
ature. After the incubation time, the wells were washed again three times with 300 µl 
of diluted Wash Buffer and 100 µl of diluted HRP solution were added to all wells. The 
plate was incubated for 1 h. After the incubation time the wells were washed three times 
with diluted Wash Buffer solution and 100 µl of TMB Substrate solution were added to 
each well. The plate was incubated in the dark for 15 min at room temperature. After the 
15  min incubation, 100 µl of Stop solution were added to each well and the absorbance 
was determined at 450 nm. The results were determined as described above.
3.2.8.  Knockdown of gene expression with short  
interfering RNA (siRNA)
Cells were trypsinized one hour or less before transfection and set aside at 37°C. siPort 
NeoFX was diluted in Opti-MEM I medium using the suggested amounts from the com-
pany and incubated for 10 min at room temperature. Next, small RNA was diluted in 
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Opti-MEM I medium for a final concentration of 10 nM. Diluted siNeoFX was combined 
with the diluted RNA, mixed by pipetting up and down and incubated 10 min at room 
temperature. The newly formed transfection complexes were dispensed into the empty 
wells of a culture 6-well plate. Cells prepared previously were seeded into the cul-
ture plate wells (at a density of 2.3 × 105 cells/well) containing transfection complexes. 
Without swirling, the plate was gently rocked back and forth to evenly distribute the 
complexes. 
Transfection of siRNA into the cells was performed with pre-designed siRNA for TLR3 
or RIG-I over 24 h. The following day, cells were stimulated with poly(I:C) (10 µg/ml) for 
12 h. The culture supernatants and cells were separated and then processed for real-
time RT-PCR analysis. Scrambled siRNA was used as the nonspecific negative control 
of siRNA. 
3.2.9.  Polyomavirus BK preparation and infection of 
HCDCs with polyomavirus (type BK) derived from 
patients with BKV reactivation
For BK virus isolation, a urine sample with a viral load of >108 copies/ml from a patient 
with a known BKV reactivation was used. The sample was inoculated for 1 h on Vero 
cells before minimal essential medium (MEM)/2% FCS was added. Viral propagation 
was monitored in the supernatant by quantitative real-time PCR with an in house-test 
on a 7500 Fast Real-Time PCR-System using primers from the Large T antigen region 
and a VIC-labeled probe (see above). At a load of 109 copies/ml, virus was harvested 
by centrifugation of the supernatant and subsequently passaged on HEK 293 cells with 
MEM/2% FCS for 60 days. Infected cells were split at 10-day intervals. Viral growth 
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was monitored by quantitative PCR and by immunofluorescence against T antigen. To 
isolate BKV, HEK 293 cells were lysed by repeated freeze-thaw cycles (3 times) and 
subsequent centrifugation at 800g for 30 min. The supernatant was adjusted to 5000 
FFUs/ml with PBS and stored at -80°C. For experiments virus was dissolved in culture 
medium and 1 ml was added to HCDCs. HCDCs were stimulated as described before.
3.2.10. Statistical analysis
Values are provided as mean ± SEM. Statistical analysis was performed by unpaired 
t-test if applicable or by analyses of variance. Significant differences are indicated for 
P-values <0.05 (*) or 0.01 (**), respectively.

CHAPTER 4
RESULTS
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4. Results
4.1.  In biopsies with PVAN, staining for polyomavirus 
(Anti-SV40) and TLR3 colocalized in epithelial 
cells of cortical tubules and the collecting duct
Polyomavirus BK exhibits a tropism for the renal tubular epithelium, particularly in distal 
nephron segments, where it establishes latent infection. Immunofluorescence double 
staining for the SV40 large T antigen (T-Ag) of polyomavirus and TLR3 in allograft biop-
sies with histological diagnosis of PVAN showed colocalization of nuclear signals for 
polyomavirus and intracytoplasmatic signals for TLR3 in epithelial cells of distal cortical 
tubules and the collecting duct (Figure 10). Intensity of immunofluorescence signals 
and SV40/TLR3 colocalization was semiquantitatively and separately assessed in med-
ullary collecting ducts and cortical tubules. The results are summarized in table 4. In 
 general, we found a great variation in SV40 and TLR3 signal intensity in the different 
biopsies, with an overall most intense TLR3 staining in medullary collecting ducts of 
PVAN. Highest semiquantitative SV40/TLR3 colocalization rates (partially >75%) were 
found in collecting ducts of the medulla in biopsies with few interstitial infiltrates. TLR 
staining in renal transplant biopsies without BKV infection was significantly less intense 
than in PVAN, and revealed a more cortical accentuated pattern with a most prominent 
TLR3 expression in cortical atrophic and dilated tubules.
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Figure 10. Immunofluorescence double staining for Toll-like receptor 3 (TLR3) and SV40 in human 
kidney biopsies with clinical and histological diagnosis of polyomavirus-associated nephropathy 
(PVAN): colocalization of polyomavirus (anti-SV40) and TLR3 protein expression in epithelial cells of 
distal cortical tubules and collecting duct. Double immunofluorescence staining of paraffin-embebed 
tissue sections of kidney needle biopsies from individuals with PVAN. Colocalization of nuclear signals 
for polyomavirus (SV40, green) and intracytoplasmic signals for TLR3 (red) in tubular epithelial cells of 
distal cortical tubules and collecting duct.
Overlay
TLR3 SV40
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Table 4. TLR3/SV40 double immunofluorescence staining in PVAN biopsies.
Immunofluorescence TLR3/SV40 colocalization
PVAN  
case no.
SV40  
positivity
TLR3  
positivity
Medullary 
 collecting 
duct
Cortex Interstitial 
infiltrates
 1 +++ Strong + Few, focal ++ ++ Moderate
 2 + Few, focal + Few ++++ +++ Few
 3 (+) Focal ++ Moderate +++ ++++ Few, focal
 4 +++ Strong + Few ++++ ++ Few
 5 + Few ++ Moderate ++ + Moderate
 6 +++ Strong ++ Moderate ++ ++ Moderate
 7 (+) Focal + Few ++++ + Few, focal
 8 (+) Focal + Few + ++ Moderate
 9 (+) Focal ++ Moderate + + Moderate
10 +++ Strong +++ Strong ++++ ++++ Absent
11 + Few +++ Strong ++ + Moderate
12 +++ Strong +++ Strong +++ ++ Severe, diffuse
13 +++ Strong + Few ++ ++ Moderate
14 +++ Strong + Few +++ + Few, focal
15 +++ Strong + Few +++ +++ Absent
16 + Few + Few ++++ +++ Few, focal
17 ++ Moderate +++ Strong ++++ ++++ Few
18 ++ Moderate +++ Strong +++ ++ Severe, diffuse
19 (+) Focal ++ Moderate ++++ +++ Few, focal
Abbreviations: PVAN, polyomavirus-associated nephropathy; TLR3, Toll-like receptor 3.
TLR3/SV40 colocalization was evaluated semiquantitatively as: +, <25%; ++, ≥25 to <50%; +++, ≥50 to 
<75%; ++++, ≥75%.
Highest medullary TLR3/SV40 colocalization rates were found in PVAN biopsies with absent or few and 
focal interstitial infiltrates. In randomly chosen renal transplant biopsies with negative immunohisto-
chemical SV40 staining, TLR3 expression was nearly absent in proximal tubules, and was strong in 
dilated atrophic tubules.
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4.2.  TLR3 mRNA expression, but not RIG-I mRNA 
expression is significantly induced in biopsies 
with PVAN compared to allograft biopsies with 
ongoing acute rejection (AR)
To compare the activation of innate immune defense mechanisms, we analysed the 
mRNA expression of TLR3 and RIG-I in the tubulointerstitial compartment of manually 
microdissected kidney biopsies. We observed a significant induction of TLR3 mRNA 
expression in the tubulointerstitial compartment of PVAN compared to renal allograft 
biopsies with AR and pretransplant donor biopsies. Despite similar inflammatory infil-
trates by immunohistochemical analysis (Table 5), the increased expression of TLR3 
mRNA in PVAN clearly differentiated them from those with AR (Figure 11a). In con-
trast, RIG-I mRNA expression was significantly induced in renal allograft biopsies with 
AR when compared to PVAN and controls (Figure  11b). As expected, according to 
the equally intense inflammatory infiltrate, the mRNA expression of CCL5/RANTES was 
 significantly upregulated in both AR and PVAN as compared to controls (Figure 11c).
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Table 5.  Histological findings and diagnoses in renal transplant biopsies 
included in the mRNA expression analysis.
PVAN Case Nr. Interstitial Infiltrates Histological diagnosis
I (+) few 
Mononuclear lymphocytes, minimal 
edema, no tubulitis
PVAN,
no viral inclusions
II + lymphocytes (>25%), focal, no 
tubulitis
PVAN, viral inclusions,
No Rejection
III ++ lymphocytes, plasma cells, few 
granulocytes (30%)
PVAN, no viral inclusions
IV ++ mononuclear lymphocytes (30%), 
minimal edema
PVAN, no viral inclusions
V ++ focal moderate (20%) PVAN, no viral inclusions
moderate interstitial Rejection
AR Case Nr. Interstitial Infiltrates Histological diagnosis
I +++ mononuclear lymphocytes, histio-
cytes (>50%), cortical and medulla, 
intense tubulitis
Acute cellular Rejection  
BANFF Ib-II
II ++ (30%) focal, mononuclear lympho-
cytes, massive edema
Acute tubulointerstitial  
Rejection BANFF I-II
III ++ focal moderate lymphocytes, 
monocytes, plasma cells, focal tubulitis
BANFF Borderline
IV +++ (>50%) lympho-plasmacellular 
infiltrates
Acute tubulointerstitial Rejection 
BANFF IIa
V ++ plasma cells, histiocytes Acute cellular Rejection  
BANFF Ib
VI ++ (>25%) lymphocytes, histiocytes, 
few plasma cells, focal tubulitis, diffuse 
edema
Acute cellular Rejection  
BANFF Ib
VII + focal lymphocytes, leucocytes, 
tubulitis
Acute vascular cellular  
Rejection BANFF IIa
VIII ++ moderate lymphocytes, few 
granulocytes
Acute vascular cellular  
Rejection BANFF IIb
IX +++ (50%) lymphocytes, histiocytes, 
few granulocytes, minimal edema
Acute cellular Rejection  
BANFF Ia
X +++ (50%) lymphocytes, histiocytes, 
few granulocytes, diffuse edema
Acute vascular cellular Rejection 
BANFF IIa
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Figure 11. Toll-like receptor 3 (TLR3), retinoic acid inducible gene-I (RIG-I) and RANTES/CCL5 mRNA 
expression in the tubulointerstitial compartment of manually microdissected renal transplant biopsies. 
(a) Expression of mRNA for TLR3 shows a significant induction in polyomavirus-associated nephropathy 
(PVAN) compared with renal allograft biopsies with acute cellular rejection (AR) and pretransplant donor 
biopsies (cadaveric donor (CD) biopsies and living donor (LV) biopsies). (b) In renal allograft biopsies with 
AR, RIG-I mRNA is significantly induced when compared with both controls and biopsies with PVAN. (c) 
RANTES/CCL5 (regulated upon activation, normal T cell expressed and secreted)/(chemokine (C-C motif) 
ligand 5) was significantly upregulated in AR and PVAN compared with pretransplant donor biopsies from 
living donors. *P<0.05; **P<0.001.
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4.3.  Expression of TLR3 and RIG-I protein on 
HCDCs in culture is enhanced after stimulation 
with poly(I:C) and proinflammatory cytokines
To confirm the expression of TLR3 protein on HCDCs, we performed FACS analysis 
with a TLR3 specific monoclonal antibody. No detectable surface staining for TLR3 was 
found on HCDCs under basal conditions. As TLR3 has been described as an intracellu-
lar, vacuolar receptor (43), HCDCs were permeabilized prior to TLR3 staining and FACS 
analysis. This resulted in a robust TLR3 staining of HCDCs (Figure 12a).
In order to test whether HCDCs might express other TLRs under basal conditions, we 
screened for mRNA of TLR1 through TLR10 by real-time RT-PCR. In addition to TLR3, 
HCDCs also robustly expressed TLR1, TLR2, TLR4, TLR5, TLR6 and TLR9 (Figure 12b). 
TLR7 and TLR10 expression was too low to allow evaluation and no expression was 
found for TLR8 (Figure 12b).
To confirm TLR3 expression and to test the expression of RIG-I protein on HCDCs, 
we conducted western blot analysis with specific monoclonal antibodies for TLR3 and 
RIG-I (Figure  12c). Non-stimulated HCDCs showed slight TLR3 and moderate RIG-I 
basal protein expression. Stimulation by poly(I:C) (10 µg/ml) as a mimetic of viral dsRNA, 
induces a significant increase in the TLR3 protein expression, whereas RIG-I protein 
expression showed only a marginal increase. Stimulation of HCDCs with a combination 
of proinflammatory cytokines (TNF-α, IL-1β and IFN-γ) combined with poly(I:C) (10 µg/ml) 
enhanced both TLR3 and RIG-I expression. HEK 293 cells were used as controls and 
showed a robust TLR3 and RIG-I protein expression. 
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Figure 12. Localization of Toll-like receptor 3 (TLR3) and expression of TLR1 to 10 and retinoic acid 
inducible gene-1 (RIG-I) in cultured human collecting duct epithelial cells (HCDCs). (a) The localiza-
tion of TLR3 protein on HCDCs was analysed by flow cytometry without and with prior permeabiliza-
tion. No TLR3 signal was found on HCDCs without permeabilization, whereas a clear signal for TLR3 
was detected after permeabilization. Open histograms represent the fluorescence activity after 
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4.4.  Expression of TLR3 and RIG-I mRNA  
increases after stimulation with poly(I:C) and 
proinflammatory cytokines
To verify our results on a transcriptional level, HCDCs were also examined for TLR3 and 
RIG-I mRNA expression. 
RNA was prepared from HCDCs growing under standard conditions as well as from 
HCDCs that had been stimulated with a combination of the cytokines TNF-α, IL-1β and 
IFN-γ for different time intervals (0, 6, 12, 24, 48 h) to simulate a proinflammatory milieu 
as would occur during ascending polyomavirus infection. By real-time RT-PCR, TLR3 
mRNA was amplified from both unstimulated (basal) and stimulated (comb) cells. The 
low basal expression for TLR3 was significantly increased with the cytokine combina-
tion in a time-dependent manner up to 48 h (Figure 13a). Similar results were found for 
RIG-I mRNA expression (Figure 13b).
 incubation with a  monoclonal anti-TLR3 antibody (Ab). Filled histograms denominate the signal of the 
appropriate isotype control. Results shown are from one of two independent experiments, which 
showed reproducible staining patterns. (b) HCDCs were cultured under basal conditions for 24  h 
before RNA extraction. Real-time reverse transcriptase (RT)-PCR was performed using primers spe-
cific for the human TLR1–10 and RIG-I as indicated in material and methods. HCDCs express TLR1, 
TLR2, TLR3, TLR4, TLR5, TLR6, TLR9 and RIG-I mRNA under basal conditions. No expression of 
TLR7, TLR8 and TLR10 mRNA was observed under the same conditions. (c) Western blot analysis for 
TLR3 and RIG-I protein expression was performed in HCDCs incubated with 10 µg/ml polyriboinosinic: 
polyribocytidylic acid (poly(I:C)) with or without prestimulation with a combination of proinflammatory 
cytokines (tumor necrosis factor-α (TNF-α), interleukine-1β (IL-1β) and interferon-γ (IFN-γ)), or medium 
alone. HEK 293 cells were used as positive control. Poly(I:C), mimicking viral double-stranded RNA 
(dsRNA), induced TLR3 and RIG-I protein expression. This effect was potentiated after prestimulation 
with the combination of cytokines (comb + poly(I:C)).
98 Activation of innate immune defense mechanisms contributes to polyomavirus BK-associated nephropathy
To test the effect of poly(I:C) on the expression of TLR3 and RIG-I mRNA, HCDCs 
were preincubated with (comb) or without (basal) the combination of proinflammatory 
cytokines (TNF-α, IL-1β and IFN-γ) for 24 hours and posteriorly incubated with or without 
poly(I:C) (10 µg/ml) for 12 hours prior to RNA extraction and real-time RT-PCR. The low 
basal expression of TLR3 (Figure 13c) and RIG-I mRNA (Figure 13d) was significantly 
enhanced by stimulation with proinflammatory cytokines (comb). Incubation with poly(I:C) 
significantly increased basal TLR3 but not RIG-I mRNA expression (Figures 13c, 13d). 
When HCDCs had been pretreated with proinflammatory cytokines, incubation with 
poly(I:C) (comb + poly(I:C)) markedly enhanced TLR3 and RIG-I mRNA expression. This 
effect was highly significant compared to basal conditions and to cytokine stimulated 
conditions (comb), respectively.
Stimulation of HCDCs with increasing concentrations of poly(I:C) (1, 5, 10 100 µg/ml) for 
12 h (white columns) slightly enhanced the basal mRNA expression of TLR3 and RIG-I 
with a maximal increase upon stimulation with 100 µg/ml of poly(I:C). Prestimulation with 
the cytokine combination (blue columns) strongly increased the poly(I:C)-induced TLR3 
and RIG-I mRNA expression (Figures 13e, 13f). Taken together, prestimulation with a 
combination of proinflammatory cytokines was a potent inducer of significant TLR3/
RIG-I upregulation.
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Figure 13. Expression of Toll-like receptor 3 (TLR3) and retinoic acid inducible gene-I (RIG-I) mRNA 
on cultured human collecting duct epithelial cells (HCDCs). HCDCs were stimulated with (Comb) or 
without (Basal) a combination of cytokines (tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and 
interferon-g (IFN-γ)) for the times indicated and levels of mRNA expression for TLR3 and RIG-I were 
analyzed by Real-time reverse transcriptase (RT)-PCR. (a) The low basal expression for TLR3 was 
increased with the cytokine combination in a time-dependent manner up to 48 h. (b) Similar results were 
found for RIG-I mRNA expression. To test the effect of TLR3 and RIG-I activation by polyriboinosin-
ic:polyribocytidylic acid (poly(I:C)), mimicking viral double-stranded RNA (dsRNA), HCDCs were preincu-
bated with (Comb) or without (Basal) the cytokine combination (TNF-α, IL-1β, and IFN-γ) and subse-
quently stimulated with and without poly(I:C) for 12 h. The mRNA expression for TLR3 and for RIG-I was 
analyzed by real-time RT-PCR. HCDCs showed low basal expression for (c) TLR3 and (d) RIG-I mRNA, 
which was induced by stimulation with proinflammatory cytokines (Comb). Incubation with poly(I:C) 
revealed a significant increase of basal TLR3, but not RIG-I, expression. (e, f) After pretreatment with 
proinflammatory cytokines, incubation with different concentrations of poly(I:C) (Comb + poly(I:C)) 
 markedly enhanced TLR3 and RIG-I mRNA expression. Data are representative of three independent 
experiments. *P<0.05; **P<0.01. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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4.5.  Activation of TLR3 and RIG-I by poly(I:C) 
significantly enhanced the mRNA expression  
of the proinflammatory cytokine IL-6, the 
chemokines RANTES/CCL5, MCP-1/CCL2,  
IL-8/CXCL8, and IP-10/CXCL10 and the  
antiviral IFN-β
To test the “downstream” effects of TLR3 and RIG-I activation by poly(I:C) mimicking viral 
dsRNA in HCDCs, we studied mRNA expression of selected cytokines and chemokines 
(IL-6, RANTES/CCL5, MCP-1/CCL2, IL-8/CXCL8 and IP-10/CXCL10). HCDCs showed low 
basal expression for IL-6 mRNA. IL-6 expression was significantly induced by stimulation 
with proinflammatory cytokines (comb). Stimulation with poly(I:C) increased IL-6 expres-
sion without preconditioning, an effect that was markedly potentiated when HCDCs had 
been preconditioned with proinflammatory cytokines (comb + poly(I:C)) (Figure 14a) in 
order to enhance their TLR3 expression. Similar results were obtained for MCP-1/CCL2 
(Figure 14c) and IL-8/CXCL8 (Figure 14d). Expression of RANTES/CCL5 (Figure 14b) 
could not be increased by poly(I:C) stimulation alone, but was increased when cells were 
preconditioned with cytokines alone (comb) and even more after cytokine precondition-
ing followed by additional poly(I:C) stimulation (comb + poly(I:C)). Basal expression for 
IP-10/CXCL10 mRNA (Figure 14e) was not detectable and after poly(I:C) stimulation only 
a slight mRNA expression for IP-10/CXCL10 was found. Pretreatment with the cytokine 
combination (comb) for 24 h resulted in a significantly increased IP-10/CXCL10 mRNA 
expression, but remained similar after additional poly(I:C) stimulation (comb + poly(I:C)). 
For the antiviral IFN-β, basal expression was moderately increased after poly(I:C) stimu-
lation, and in parallel to the chemokines studied afore, preconditioning with the cytokine 
combination revealed a significant increase in IFN-β mRNA expression (Figure 14f).
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Figure 14. Effect of polyriboinosinic:polyribocytidylic acid (poly(I:C)) and cytokine prestimulation on the 
mRNA expression of selected cytokines and chemokines. Human collecting duct epithelial cells (HCDCs) 
were pretreated with (Comb) or without (Basal) a cytokine combination (tumor necrosis factor-α	(TNF-α), inter-
leukin-1β (IL-1β), and interferon-γ (IFN-γ)) for 24 h and incubated with or without poly(I:C) for 12 h. mRNA levels 
for IL-6 (a), MCP-1/CCL2 (c), Il-8/CXCL8 (d), IP-10/CXCL10 (e) and IFN-β (f) slightly increased after stimulation 
with poly(I:C), an effect potentiated after pretreatment with the cytokine combination. (b) Expression of 
RANTES/CCL5 was not increased by poly(I:C) without preconditioning, but was increased by preconditioning 
with cytokines alone (Comb) and even more after cytokine preconditioning followed by additional poly(I:C) 
stimulation (Comb + p(I:C)). Data are representative of three independent experiments. *P<0.05; **P<0.01.
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4.6.  Knockdown of TLR3 with siRNA inhibits the 
poly(I:C) induced expression of IL-6 and IFN-β in 
cultured HCDCs, whereas knockdown of RIG-I 
had no effect on the expression of both cytokines
Knockdown experiments using the respective short interfering RNAs (siRNAs) were 
performed to evaluate which of the two receptors (TLR3 or RIG-I) might be involved 
in the IL-6 and IFN-β response to poly(I:C) stimulation. HCDCs were transfected with 
siRNA for TLR3 (siTLR3) or RIG-I (siRIG-I) and were stimulated with poly(I:C) (10 µg/ml), 
mimicking viral dsRNA, for 12 h. IL-6 and IFN-β expression was analysed by real-time 
RT-PCR (Figure 15a, 15b) and ELISA (Figure 15c). 
The poly(I:C) induced IL-6 and IFN-β mRNA expression was significantly reduced in 
cells pretreated with siRNA for TLR3. In contrast, siRNA for RIG-I did not significantly 
decrease the poly(I:C) induced IL-6 or IFN-β mRNA expression (Figure 15a, 15b). ELISA 
for IL-6 confirmed the poly(I:C)-induced upregulation of IL-6 protein, which was also only 
attenuated by siRNA for TLR3, but not by siRNA for RIG-I (Figure 15c). ELISA for IFN-β 
was also performed but no protein expression was observed maybe due to the low 
sensitivity of the used ELISA kit.
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4.7.  Infection of cultured HCDCs with BKV resulted 
in a significant increase of IL-6, IL-8/CXCL8 and 
TLR-3 and RIG I expression
In order to simulate an ‘in vivo’ model of BKV infection of the distal nephron segment, HCDCs 
were infected with BKV as described above. To evaluate the expression of TLR3, RIG-I and 
cytokines in response to a viral infection, the cells were incubated with BKV for different time 
intervals (3, 6, 9, 12, 24 h). As a read-out system for effective viral infection of HCDCs, we ana-
lyzed the expression of BKV Large T-Antigen (large T-Ag), representing a marker protein of 
the early phase of BKV infection. Highest expression of Large T-Antigen was detected at 3 h 
post infection by real-time RT-PCR and decreased in a time-dependent manner (Figure 16a).
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Figure 15. Effect of transfection with short interfering RNA (siRNA) for Toll-like receptor 3 (TLR3) or reti-
noic acid inducible gene-I (RIG-I) on the expression of IL-6 and IFN-β. Human collecting duct epithelial 
cells (HCDCs) were transfected with siRNA specific for TLR3 or RIG-I and stimulated with polyriboinosin-
ic:polyribocytidylic acid (poly(I:C)) for 12 h. (a) Poly(I:C) significantly increased IL-6 mRNA expression, an effect 
that was significantly attenuated by siRNA specific for TLR3. In contrast siRNA for RIG-I did not significantly 
reduced IL-6 mRNA expression. (b) IFN-β mRNA expression was significantly increased after poly(I:C) stim-
ulation, an effect that was significantly attenuated in cells pretreated with siRNA for TLR3 but not in cells 
pretreated with siRNA for RIG-I. (c) IL-6 mRNA expression was confirmed by enzyme-linked immunosorbent 
assay (ELISA) but IFN-β mRNA expression could not be confirmed on protein level. Data are representative 
of three independent experiments. *P<0.05; **P<0.01; NT, non-targeting Negative Control siRNA.
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Basal TLR3 and RIG-I mRNA expression showed a slight increase during HCDC culture 
over 24 h and after infection with BKV the mRNA expression of both receptors was 
markedly upregulated at 12 h, and then immediately decreased (Figures 16b, 16c). 
The TLR3 adaptor molecule TRIF showed a robust constitutive basal expression in 
HCDCs but BKV exposure was not able to enhance TRIF expression in our model, as 
determined by real-time RT-PCR (Figure 16d). To test potential effects of BKV infection 
on selected cytokine and chemokine generation by HCDCs, we determined IL-6 and 
IL-8/CXCL8 expression by real-time RT-PCR. Under basal conditions, HCDCs in culture 
showed a slight constitutive expression of both IL-6 and IL-8/CXCL8, an effect that was 
potentiated after BKV exposure. IL-6 mRNA showed a marked increase at 3 h and a 
moderate, but still highly significant increase 6 h after infection (Figure 16e). Similar 
results were obtained for the chemokine IL-8/CXCL8 with a prominent mRNA expres-
sion at 3 and 6 h and a return towards baseline at 9 h post infection (Figure 16f). IL-6 
and IL-8/CXCL8 protein expression was determined by ELISA. Under basal conditions, 
HCDCs showed a constitutive expression of both IL-6 and IL-8/CXCL8 (Figures 16g, 
16h). After BKV exposure, IL-6 showed a significant and robust increase at all time 
points, with highest absolute levels at 9 h post infection (Figure 16g). In contrast, IL-8/
CXCL8 was not elevated at 3 h post infection, but showed a constant significant upreg-
ulation at 9, 12 and 24 h after BKV infection (Figure 16 h).
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Figure 16. Infection of cultured human collecting duct epithelial cells (HCDCs) with BK virus (BKV) 
results in a significant increase of cytokine and chemokine expression and upregulation of dou-
ble-stranded RNA (dsRNA) receptors Toll-like receptor 3 (TLR3) and retinoic acid inducible gene-I 
(RIG-I). HCDCs were infected with BKV and were then incubated for different time intervals (3, 6, 9, 12, 
and 24 h). (a) Highest levels of large T antigen (T-Ag), a marker protein of the early phase of BKV infec-
tion, were detected at 3 h post infection by real-time reverse transcriptase (RT)-PCR and decreased in 
a time-dependent manner. (b, c) Basal TLR3 and RIG-I mRNA expression showed a slight increase 
during incubation over 24 h. BKV infection upregulated both receptors at 12 h post infection with a sub-
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4.8.  Poly(I:C) or poly(dA:dT) stimulation, but not BKV 
infection, induced the transcription of NLRP-3 
and AIM2 in HCDCs
Activation of TLR3/RIG-I and robust IL-6 and IL-8/CXCL8 upregulation after BKV expo-
sure was a consistent feature in our ‘in vivo’ model of BKV infection. During initial BKV 
infection of HCDCs, it is likely that different DNA and RNA sensing pathways are trig-
gered simultaneously in order to potentiate antiviral responses to infection. Recogni-
tion by these sensing pathways could finally lead to the assembly of inflammasome 
complexes that activate caspase-1, leading to production of IL-1β and IL-18. To test 
this hypothesis, we studied the expression of (i) IL-1β, an important proinflammatory 
cytokine that is secreted after assembly of inflammasome complexes, (ii) the inflam-
masome components NLRP-3 and caspase-1 and (iii) AIM2, a newly discovered patho-
gen recognition receptor involved in the sensing of cytosolic DNA produced by infection 
with DNA viruses (22, 78, 186). Since NLRP3 and AIM2 inflammasomes are located 
in the cytoplasm, we first examined whether transfected poly(I:C) or poly(dA:dT) can 
induce NLRP3 and AIM2 expression in HCDCs as well as caspase-1 and IL-1β, which 
are known to be activated downstream to these inflammasome signaling pathways. 
We found a clear increase of NLRP3 mRNA expression after treatment with poly(I:C), 
as well as after treatment with poly(dA:dT) (Figure 17a). NLRP3 expression induced by 
poly(I:C) or poly(dA:dT) is time dependent with the maximum expression at 24 h after 
sequent decrease. (d) The basal expression of TIR-domain-containing adaptor-inducing interferon-β 
(TRIF) was not significantly affected over the time, after BKV infection. (e) Under basal conditions, cul-
tured HCDCs showed a low expression of interleukin-6 (IL-6), which increased significantly after BKV 
exposure. (f) Similar results were obtained for the chemokine IL-8/CXCL8. (g, h) Protein secretion of IL-6 
and IL-8/CXCL8 was confirmed by enzyme-linked immunosorbent assay (ELISA) technique. Data are 
representative of three independent experiments. *P<0.05; **P<0.01.
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stimulation. AIM2 mRNA was also significantly upregulated by poly(I:C) or poly(dA:dT) 
in these cells being the maximum expression also after 24 h (Figure 17b). Concordant 
with these results, poly(I:C), as well as poly(dA:dT) were able to induce caspase-1 and 
IL-1β mRNA expression in HCDCs (Figures 17c, 17d). ELISA and western blot analysis 
for IL-1β were performed under exactly the same conditions in order to confirm these 
results on protein level but no protein expression was observed. 
After BKV infection we found a very low basal IL-1β mRNA expression with a slight, but 
not significant increase at 3 and 12 h post infection and a significant increase at 6 and 
9 h post infection, decreasing the expression almost until the basal levels after 24 h 
(Figure 17e). This marginal upregulation could not be confirmed by ELISA technique. 
Caspase-1, NLRP3 and AIM2 expression was not induced by BKV infection.
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Figure 17. Polyriboinosinic:polyribocytidylic acid (poly(I:C)) and poly(deoxyadenylic- deoxythymidylic) 
acid (poly(dA:dT)) but not BK Virus (BKV) infection promoted the expression of NLRP3, AIM2, 
caspase-1 and IL-1β mRNA. Human collecting duct epithelial cells (HCDCs) were transfected with 
poly(I:C) or poly(dA:dT) or infected with BKV for different time intervals (3, 6, 9, 12 and 24 h). (a) NLRP3 
mRNA expression induced by poly(I:C) or poly(dA:dT) increased in a time dependent manner up to 24 h 
after transfection. (b, c, d) Similar results were found for AIM2, caspase-1 and IL-1β mRNA expression. 
(f) BKV infection significantly upregulated the expression of IL-1β mRNA at 6 h and 9 h post infection, 
with a subsequent decrease up to 24 h. Data are representative of three independent experiments. 
*P<0.05; **P<0.01.
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5. Discussion
PVAN due to BKV reactivation is an increasingly recognized complication in renal trans-
plant recipients leading to graft dysfunction and premature graft loss in up to 10% of 
the patients. 
Stronger immunosuppressive regimens have decreased the rates of acute rejection in 
kidney transplantation, but have also led to the emergence of PVAN, by supporting viral 
replication (164). Unfortunately there are no drugs with proven efficacy for BKV replica-
tion. Although a number of centers have adopted the use of cidofovir or leuflunomide, 
some in vitro studies suggested a limited therapeutic efficacy of these agents asso-
ciated to potential clinical toxicities (187, 188). Therefore, an early diagnosis of PVAN 
by histology in combination with timely reduction in immunosuppression are the only 
proven measures that can circumvent irreversible parenchymal damage (172). 
Despite the critical role that PVAN may play in long-term graft loss, there is surprisingly 
little known about the immunology of BKV infection and particularly about the intra-graft 
cellular immune response after renal transplantation. In the current study, we present 
results suggesting that in PVAN critical viral dsRNA sensors are involved in the antiviral 
response in the infected renal epithelia.
The presence of viral dsRNA in the cell is a signature of virus infection, which activates 
cellular sensors of the innate immune system to induce host cellular responses that 
have a key role in controlling virus infection (16, 21). dsRNA can be generated as a 
replication intermediate for ssRNA virus or as a by-product of symmetrical transcrip-
tion in DNA virus. Thus, for three reasons we evaluated the potential role of critical viral 
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sensors for dsRNA in PVAN: (i) dsRNA is produced by most viruses (including polyo-
mavirus BK with a circular dsDNA genome) at some point during their replication (42); 
(ii) during promiscuous transcription, the intracellular concentration of dsRNA is further 
increased (about 20% of the polyomavirus RNA in infected cells consists of partially 
doublestranded  molecules during transcription in the late stage) (189, 190); (iii) BKV 
RNA, indicating active viral replication, was found in all BKV DNA positive biopsies in a 
recent gene expression study of renal transplant biopsies (104). 
During replication of DNA or RNA viruses and exposition with immune complexes, the 
host cells contact with viral (ss) or (ds) RNA triggering a specific immune response to 
the viral infection including NF-κB target genes, type I IFNs, and IFN response genes. 
Among the receptors involved in sensing viral particles, TLR3, which is expressed in 
the endosome of the cell, is known to be involved in the recognition of viral dsRNA 
and its synthetic analogue poly(I:C). TLR3 can be expressed by conventional DCs and 
macrophages (6) as well as by a variety of nonimmune cells such as glomerular mesan-
gial cells (44), endothelial cells and epithelial cells (191). TLR3 deficiency is associated 
with susceptibility to several viral infections such as MCMV infection in mice and HSV-1 
infection in humans (103, 180). However, evidence to date shows that TLR3 is not uni-
versally required for the generation of effective antiviral responses. Some studies have 
shown that TLR3-deficient mice were more resistant to infection by West Nile virus 
(WNV) and influenza virus suggesting that TLR3-mediated recognition contributes to 
the pathogenesis rather than protection in the case of these infections (192, 193). In this 
situation, RNA helicases represent an alternative major cellular sensor for several viral 
infections associated with dsRNA (47). When the virus enters in the cytoplasm, dsRNA 
generated during the course of viral replication is sensed by the host cell, an event that 
is independent of TLR3 (16). In this regard, RLRs seem to be critical to recognize viral 
RNA in the cytoplasm (6). We, therefore, looked at TLR3 and the RNA helicase RIG-I, 
which may also function as cytosolic alternative pattern recognition receptor of viral 
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motifs (13, 14, 194). However, a critical cooperation of the RIG-I/MDA5-type I IFN and 
the TLR3-type II IFN signaling axes may be required for efficient innate antiviral immune 
responses (195).
We previously reported that in human kidney, immunohistochemical staining shows 
TLR3 expression in glomeruli with a mesangial pattern, in vascular smooth muscle cells 
of preglomerular vessels and in collecting duct epithelial cells, suggesting a pivotal 
pathogenic role of this receptor (44). As BKV normally replicates in urothelial cells but 
it can also exhibit tropism for the renal tubular epithelium (126, 127), we first examined 
whether TLR3 and polyomavirus BK protein colocalize in the same cells of the collect-
ing tubules. Immunofluorescent staining of renal biopsies with PVAN did, in fact, co- 
localize polyomavirus (Anti-SV40) and TLR3 protein expression in tubular epithelial cells 
of cortical collecting tubules. SV40 Large T-antigen showed strong nuclear positivity in 
the renal epithelium, whereas the staining pattern for TLR3 was most consistent with 
tubular membrane localization (Figure 10). 
The features of PVAN are in many cases very similar to those associated to AR, and 
thus, a similar inflammatory response can be expected. Cellular inflammatory infiltrates 
and mRNA expression profiles of inflammatory cytokines and chemokines in PVAN and 
in biopsies with AR are similar in composition and quantity. This is particularly true for 
RANTES/CCL5 (146). During an episode of inflammation, several inflammatory markers 
are expressed by the cells at the site of infection. Among these markers, RANTES/CCL5 
plays a primary role in the inflammatory immune response due to its ability to chemoat-
tract leukocytes into inflammatory sites and to modulate their function (196). Here, we 
observed that RANTES was indeed significantly upregulated in both AR and PVAN 
biopsies compared to controls, confirming relevant inflammation (Figure 11c). On the 
other hand, TLR3 mRNA expression segregated PVAN from transplant biopsies with AR 
(Figure 11a). TLR3 mRNA expression, but not RIG-I mRNA expression, was significantly 
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induced in allograft biopsies with PVAN compared to those with ongoing AR (Figures 
11a, 11b). In contrast, RIG-I mRNA was significantly induced in AR, an observation 
deserving further investigation (Figure 11b).
Based on these data, we hypothesized that particularly TLR3 could be a receptor can-
didate to mediate activation of innate immunity in PVAN. Our hypothesis was under-
scored by the following two recent findings: (i) TLR3 resides in the endosomal mem-
brane and the endoplasmic reticulum and moves to dsRNA-containing endosomes in 
response to dsRNA (178). Since BKV has previously been shown to enter cells through 
endocytosis, viral dsRNAs could activate TLR3 during BKV infection of tubular epithelial 
cells upon viral entry and uncoating in the endosome; (ii) activation of the TLR3 pathway 
was described in various viruses containing a dsDNA genome, e.g. KSHV (179), HSV-1 
(180, 181) and murine CMV (103).
To further elucidate a potential role of dsRNA receptors in PVAN, we used a cell culture 
model of collecting tubule origin (HCDCs), the predominant site of renal BK infection 
(150). First, we confirmed that the immortalized HCDC line expresses dsRNA receptors 
under basal conditions. A robust basal mRNA and protein expression for TLR3 as well 
as for RIG-I was demonstrated by real-time RT-PCR and western blot analysis (Figures 
12b, 12c). TLR3 was localized by FACS analysis in HCDCs intracellularly (Figure 12a). 
Localization of TLR3 in the endosomal membranes of the collecting duct would expose 
the receptor to the endocytosed virus during BKV infection, as discussed above.
To characterize the activation of innate immune mechanisms in PVAN we prestimulated 
HCDCs with a cytokine combination to establish a proinflammatory milieu in cell cul-
ture, as might occur during viral infection. In addition we exposed the cells to poly(I:C), 
a synthetic mimetic of viral dsRNA, to simulate aspects of viral infection. The basal 
expression of both TLR3 and RIG-I mRNA in HCDCs was increased by prestimulation 
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with the combination of cytokines in a dose-dependent manner (Figures 13a, 13b). The 
expression of TLR3, and RIG-I mRNA was also enhanced after stimulation with poly(I:C) 
(Figures 13c, 13d, 13e, 13f). The concentration of poly(I:C) required for these effects are 
in the range of those reported by others for these receptors (197).
Human tubular epithelial cells are known to interact both with neighbouring cells and 
with the immune system through the production of cytokines and chemokines, such as 
IL-6, IL-8/CXCL8, IL-15, TNF-α, MCP-1, RANTES, and TGF-β (198, 199, 200), which are 
responsible for local inflammatory reactions, as well as some systemic effects. These 
responses are required to initiate a cellular and humoral immune response to control 
infection, but can also result in tissue injury and dysfunction, as evidenced in PVAN (139). 
We, therefore, investigated the role of selected cytokines and chemokines in HCDCs. 
Activation of viral receptors by poly(I:C) significantly enhanced the mRNA expression of 
various cytokines and chemokines (IL-6, IL-8/CXCL8, RANTES/CCL5, MCP-1/CCL2 and 
IP-10/CXCL10) in these cells after poly(I:C) stimulation (Figures 14a, 14b, 14c, 14d, 14e). 
These findings are in accordance with data from Mannon and co workers, who reported 
elevated levels of RANTES, TNF-α, TNF-β and activation markers of macrophages in 
PVAN (146). In addition, increased urinary excretion of MCP-1 is associated with intra-
graft tubulointerstitial inflammation in patients with PVAN (201).
In order to identify which viral receptors might contribute to the generation of cytokines 
and chemokines, we knocked down the receptor expression by transfection with the 
corresponding siRNA. The poly(I:C) induced expression of IL-6 in cultured HCDCs was 
significantly inhibited by transfection with siRNA for TLR3, whereas transfection with 
siRNA for RIG-I had no significant effect on IL-6, suggesting a pivotal role of TLR3 in this 
scenario (Figures 15a, 15b).
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Finally, we established an infection model using cultured HCDCs and BKV isolated 
from urine of patients with known BKV reactivation. After BKV infection, the mRNA 
expression for IL-6 and IL-8/CXCL8 increased (Figures 16e, 16f). This early cytokine 
and chemokine activation was followed by a time-dependent significant increase of 
TLR3 and RIG-I expression with maxima at 12 h post infection, whereas BKV infection 
could not enhance the robust constitutive basal expression of TRIF (Figures 16b, 16c, 
16d). Recently, Low and colleagues described primary human proximal tubule epithelial 
(HPTE) cells, another major cell type that can be infected by BKV ‘in vivo’, as a model 
system for lytic BKV infection (202). Subsequent studies using this model found a pri-
mary activation of genes involved in cell cycle regulation and apoptosis (203). Of par-
ticular note, the HPTE model was not able to elicit an antiviral immune response in the 
given experimental context.
Our results differ in two major points from the HPTE model. First, HCDCs significantly 
expresse large T-antigen, a marker protein of the early phase of BKV infection, at a 
very early stage of infection (3 h post infection) (Figure 16a), whereas in the HPTE 
model early viral gene expression was first detectable at 24 h post infection with  levels 
increasing out to 72 h post infection. These findings suggest that BKV infection of 
HCDCs involves particularly the early phase of BKV infection with a more rapid viral 
trafficking through the cytoplasm than in HPTE cells. Second, the distinctive cytokine 
and chemokine activation after BKV infection, demonstrated by significant IL-6 and 
IL-8/CXCL8  upregulation, was a prominent early signature in our model. In contrast, a 
cytokine-targeted PCR array analysis of the HPTE model performed at 4 h post infec-
tion revealed no proinflammatory response to BKV infection (203).
Even basal TLR3 and TRIF expression was sufficient for significant early cytokine/
chemokine activation in our infection model. This initial early cytokine and chemokine 
activation seems to be independent of efficient virus replication, as demonstrated also, 
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in for example, rhinovirus-induced airway epithelial cells (204, 205) and apparently starts 
an efficient antiviral response in HCDCs, leading to a transient robust dsRNA receptor 
expression as demonstrate by significant TLR3 and RIG-I expression.
Activation of TLR3 and RIG-I after stimulation with synthetic dsRNA was a consistent 
feature in cultured HCDCs, and upregulation of both receptors was confirmed in our 
infection model mimicking the early infection phase of the collecting duct by BKV. In 
contrast, we found a robust TLR3, but unexpectedly no significant RIG-I expression in 
biopsies with PVAN. How can this obvious discrepancy be reconciled? Although infec-
tion models try to roughly copy the BKV infection of target cells, these are acute models 
and may not exactly reproduce the ‘in vivo’ situation in clinically conspicuous PVAN 
captured by renal biopsy in a late phase of the viral infection. During initial BKV infection 
of HCDCs, it is likely that different DNA- and RNA-sensing pathways are triggered simul-
taneously, leading to a parallel upregulation of various receptors. This crosstalk between 
different innate immunity pathways could eventually potentiate antiviral responses to 
infection. Potential signaling pathways other than NF-κB or IFN that are activated upon 
viral recognition and mediate antiviral responses have been recently suggested (23, 
24, 206). This includes the cytoplasmic multiprotein complexes called inflammasomes, 
which mediate activation of caspase-1 and promotes the secretion of the proinflamma-
tory cytokine IL-1β. After secretion from the cell, IL-1β induces several biological effects 
that are associated with infection and inflammation (207). Recently, Thomas and cow-
orkers and Allen and coworkers (208, 64) suggested an involvement of NLRP3 inflam-
masome in the host response against influenza virus and Kanneganti and colleagues 
(209) have also proposed a role for NLRP3 in response to viral infection and dsRNA. 
Poly(I:C) was also suggested as being able to activate NLRP3 (210). In addition Alnemri 
and coworkers (78) identified AIM2 inflammasome as a potential candidate to sense 
cytoplasmic DNA. To confirm if HCDCs would express NLRP3 or AIM2 in response to 
dsRNA or dsDNA, we stimulated the cells with poly(I:C) or poly(dA:dT). Consistent with 
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previous results we observed that poly(I:C) is able to induce NLRP3 mRNA expression in 
HCDCs (Figure 17a). Poly(dA:dT) also induces NLRP3 mRNA expression in this cell line 
model (Figure 17a). AIM2, known as a receptor for cytoplasmic DNA, was upregulated 
after exposure to poly(dA:dT) (Figure 17b), confirming previous data from other work 
groups. However, interestingly, AIM2 mRNA expression appears to be also induced by 
poly(I:C) on these cells (Figure 17b), but as no other data supporting this observation is 
available, further studies are absolutely necessary in order to elucidate the mechanisms 
of activation of AIM2 by dsRNA. As expected, caspase-1 and IL-1β mRNA expression 
was also induced by poly(I:C) and poly(dA:dT) in HCDCs (Figures 17c, 17d) suggest-
ing an inflammatory response initiated by the activation of the inflammasome pathway. 
However, no results were obtained on protein level impeding us of taking conclusions 
about the activation of inflammasome pathway by poly(I:C) or poly(dA:dT) on these cells. 
As it was mentioned above, NLRP3 and AIM2 appear to be involved in the recognition 
of several viruses. In this sense, and after observation that HCDCs express NLRP3 and 
AIM2 mRNA after exposure to poly(I:C) or poly(dA:dT), we hypothesized an involvement 
of these receptors in PVAN. However, we were not able to demonstrate activation/
upregulation of NLRP3 inflammasome pathway or AIM2 pathway in our ‘in vivo’ model 
of BKV infection. Although we observed an increase of IL-1β mRNA expression after 
BKV infection (Figure 17e), this data could not be confirmed on protein level suggesting 
that inflammasome pathway is not activated by BKV on these cells.
A detailed analysis of the observed differences in dsRNA receptor activation between 
PVAN and AR should now be an important area of future study and could also have a 
significant impact on the demanding histological differentiation of these two inflamma-
tory conditions. The striking upregulation of RIG-I mRNA expression in AR has now to 
be confirmed in  larger-scale studies and with immunohistochemical or immunofluores-
cence techniques. On the basis of our findings, it is questionable whether TLR3 mRNA 
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expression analysis or TLR3 immunohistochemistry has the potential to serve as an 
additional diagnostic tool to discriminate PVAN biopsies from those with acute ongoing 
rejection, as TLR3 expression is not a unique feature of PVAN. Although TLR3 immuno-
fluorescence signals were most intense in medullary collecting ducts of PVAN, and were 
independent of concomitant inflammation, we also observed distinct TLR3 staining in 
cortical atrophic and dilated tubules of AR.
Taken together, we were able to show significant activation of proinflammatory cytokines, 
chemokines and the dsRNA receptors TLR3 and RIG-I in cultured HCDCs after poly(I:C) 
and cytokine stimulation and in a BKV infection model, mimicking polyomavirus BK 
infection of collecting duct tubules. Immunofluorescence double staining of BKV and 
TLR3 in the collecting tubular epithelial cells and mRNA expression analysis of biopsies 
with PVAN suggest that activation of innate immune defense mechanisms, particularly 
via TLR3, is involved in the antiviral and inflammatory response. 
In future studies, the interaction of TLR3 with additional viral sensors, for example cyto-
solic sensors of dsDNA, and the role of RIG-I for driving inflammation in PVAN will have 
to be elucidated. To better identify the cellular and molecular events of BK polyomavirus 
infection it would also be important to investigate how the activation of viral receptors of 
innate immunity regulates an adaptive response in PVAN. Finally, as the use of immuno-
suppressor agents in the treatment of AR increases the emergence of PVAN, it is also 
an attractive topic for future studies to elucidate how the immunosuppressor agents can 
influence the innate immune response to the virus. 
Concluding, the goal of this study was to identify innate antiviral responses initiated in 
PVAN. The identification of specific signal cascades activated during the viral infection 
of renal cells should allow us to identify novel markers that could play an essential role 
in this disease and then identify therapeutic strategies and potentially unique targets of 
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intervention. In the future it will be important to determine which viral immune evasion 
genes are critical for persistence ‘in vivo’, so that these genes can be specifically tar-
geted for pharmacologic intervention.
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Abbreviations
Ab – Antibody
AIM2 – Absent in melanoma 2
AR – Acute rejection 
APC – Antigen presenting cell
BIR –  Baculovirus “inhibitor of apoptosis” repeat domain
BKV – BK virus
BSA – Bovine serum albumine
CARD – Caspase recruitment domain
Cardif – CARD adaptor inducing IFN-β
CCL – Chemokine (C-C motif) ligand
cDNA – Complementary DNA
CMV – Cytomegalovirus
CpG – Cytidine-phosphate guanosine
CTL – Cytotoxic T lymphocytes
DC – Dendritic cell
DED – Dead effector domain 
DMEM – Dulbecco’s modified Eagle´s medium
DNA – Deoxyribonucleic acid
DNTPs – Deoxynucleotide triphosphates
dsDNA – Double stranded DNA
dsRNA – Double stranded RNA
EC – Epithelial cell
EBV – Epstein-Barr virus
ELISA – Enzyme-linked immunosorbent assay
EMCV – Encephalomyocarditis virus 
FACS – Fluorescence-activated cell sorting
FADD –  FAS-associated death domain-containing protein 
FCS – Fetal calf serum
FITC – Fluorescein isothiocyanate
HCDCs – Human collecting duct epithelial cells
HIV – Human immunodeficiency virus 
HSV-1 – Herpes simplex virus
IKK – IκB kinase
IL – Interleukin
IL-1R – Interleukin-1 receptor
IFN – Interferon 
IPS-1 – IFN-β promoter stimulator 1
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IRAK – Interleukin-1 receptor associated kinase
IRF – Interferon regulatory factor
ISRE – IFN-sensitive response element 
KSHV – Kaposi´s sarcoma-associated herpesvirus
LGP2 – Laboratory of genetics and physiology-2
MAVS – Mitochondrial antiviral signaling protein
MCP-1 – Monocyte chemoattractant protein
MDA5 –  Melanoma differentiation associated protein 5
MyD88 – Myeloid differentiation protein 88
NALP3 – NACHT-LRR-PYD-containing protein 3
NF-κB – Nuclear factor κB
NK – Natural killer
NLR – Nod-like receptor
NOD – Nucleotide-binding oligomerization domain
PAMP – Pathogen associated molecular pattern 
PBS – Phosphate-buffered saline
PCR – Polymerase chain reaction 
Poly(dA:dT) – Poly(deoxyadenylic-deoxythymidylic) acid
Poly(I:C) – Polyriboinosinic:polyribocytidylic acid
PRR – Pathogen recognition receptor
PVAN – Polyomavirus-associated nephropathy
PYD – Pyrin domain 
RANTES –  Regulated upon activation, normal T cells expressed and secreted
RSV – Respiratory syncytial virus 
RIG-I – Retinoic acid-inducible gene-I
RIP-1 – Receptor-interacting protein 1 
RIPA – RadioImmunoPrecipitation assay
RLR – RIG-I-like receptor
RNA – Ribonucleic acid
RT – Reverse transcriptase
siRNA – Small interfering RNA
ssRNA – Single stranded RNA
ssDNA – Single stranded DNA
TBST – Tris-buffered salin-Tween
TIR – Toll/interleukin-1 receptor domain
TLR – Toll-like receptor
TNF – Tumor necrosis factor
TRAF – TNF receptor associated factor
TRAM – TRIF related adaptor molecule
TRIF – TIR-domain-containing adaptor-inducing interferon-β
VISA – Virus-induced signaling adapter
WNV – West Nile virus 
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